Page last updated: 2024-12-04

uracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1174
CHEMBL ID566
CHEBI ID17568
SCHEMBL ID8235
MeSH IDM0022302

Synonyms (165)

Synonym
BB 0242167
nsc-3970
2,3h)-pyrimidinedione
2,4-pyrimidinediol
URA ,
pirod
nsc3970 ,
2,4-pyrimidinedione
hybar x
2,4-dihydroxypyrimidine
ru 12709
pyrod
2,4-dioxopyrimidine
CHEBI:17568 ,
urazil
pyrimidine-2,4(1h,3h)-dione
24897-50-5
nsc29742
nsc-29742
NCIMECH_000782
NCI60_003718
uracil [usan]
nsc 3970
einecs 200-621-9
AC-907/30002021
pyrimidine-2,4-diol
uracil (jan/usan)
D00027
NCGC00181030-01
smr000752912
MLS001304993
1h-pyrimidine-2,4-dione
2,4(1h,3h)-pyrimidinedione
inchi=1/c4h4n2o2/c7-3-1-2-5-4(8)6-3/h1-2h,(h2,5,6,7,8
4-hydroxy-2(1h)-pyrimidinone
ai3-25470
sq 6201
uracil (8ci)
2-hydroxy-4(3h)-pyrimidinone
sq 7726
sq 8493
2-hydroxy-4(1h)-pyrimidinone
bms 205603-01
2,4(1h,3h)-pyrimidinedione (9ci)
ccris 3077
STK301734
C00106
uracil ,
66-22-8
uracil, >=99.0%
uracil, suitable for cell culture, bioreagent
1UI0
DB03419
E2FC11E5-1887-46DF-B415-82313CE9B2BD
BMSE000187
CHEMBL566
sq-6201
lamivudine impurity e rs
lamivudine impurity e
fluorouracil specified compound c
sq-8493
sq-7726
bms-205603-01
pyrimidine-2,4-dione
FT-0695908
FT-0695907
FT-0694063
U0013
AKOS000119989
AKOS002303991
1h-pyrimidine-2,4-dione;uracil
A835376
STL124066
NCGC00247663-01
HMS3264C13
uracil [usan:jan]
unii-56hh86zvct
56hh86zvct ,
tox21_112680
NCGC00258576-01
cas-66-22-8
tox21_201023
dtxcid101424
dtxsid4021424 ,
nsc759649
nsc-759649
pharmakon1600-01502345
BMSE000940
66255-05-8
4-hydroxyuracil
HMS2234E19
S4177
CCG-35866
FT-0609769
PS-5279
lamivudine impurity f [ep impurity]
uracil [who-dd]
uracil [inci]
uracil [usp-rs]
lamivudine impurity e [usp impurity]
fluorouracil impurity c [ep impurity]
uracil [mi]
uracil [mart.]
uracil [jan]
fluorouracil specified compound c [usp impurity]
EPITOPE ID:120356
51953-14-1
HMS3373E18
1,2,3,4-tetrahydropyrimidine-2,4-dione
gtpl4560
CCG-213042
AB00918623-05
AM83913
SCHEMBL8235
NCGC00181030-02
tox21_112680_1
uracil-5-d1
144104-68-7
2,4-(1h,3h)-pyrimidinedione
CS-W020104
2,6-dihydroxypyrimidine
2,4-dioxypyrimidine
AB00171810_03
AB00171810_04
24897-51-6
mfcd00006016
F1796-0008
uracyl
uracil, >=99.0% (t)
uracil, united states pharmacopeia (usp) reference standard
HMS3652N05
uracil, pharmaceutical secondary standard; certified reference material
uracil, vetec(tm) reagent grade, 98%
uracil, 99%
fluorouracil impurity c, european pharmacopoeia (ep) reference standard
2,6-dioxypyrimidin
pyrimidine-2,4(1h,3h)-dione (uracil)
HY-I0960
Z56889474
SW220239-1
8h-uracil
hydroxypyrimidinone
FT-0773727
uracil,(s)
fluorouracil impurity c
BCP26546
Q182990
cid 5274267
uracil-6-d1
SB55489
SB55884
4(3h)-pyrimidinone,2-hydroxy-(9ci)
SY008943
bdbm50549809
EN300-17138
uracil (usp-rs)
2-hydroxy-4-(1h)-pyrimidione
lamivudine impurity f (ep impurity)
fluorouracil impurity c (ep impurity)
4-hydroxy-2-(1h)-pyrimidione
uracil (mart.)
lamivudine impurity e (usp impurity)
2, 4-dioxopyrimidine
fluorouracil specified compound c (usp impurity)
2-hydroxy-4-(3h)-pyrimidione

Research Excerpts

Overview

Uracil is an unavoidable aberrant base in DNA, the repair of which takes place by a highly efficient base excision repair mechanism. Uracil was found to be a dominant nucleotide in both poppy pre-miRNA sequences (31.28 +/- 7.06% of total nucleotide composition) and in the first position at the 5' end of mature poppy miRNAs.

ExcerptReferenceRelevance
"Uracil is an unavoidable aberrant base in DNA, the repair of which takes place by a highly efficient base excision repair mechanism. "( Excision of uracil from transcribed DNA negatively affects gene expression.
Epe, B; Khobta, A; Lühnsdorf, B, 2014
)
2.22
"Uracil is an essential biomolecule for terrestrial life, yet its prebiotic formation mechanisms have proven elusive for decades. "( Anionic derivatives of uracil: fragmentation and reactivity.
Bierbaum, VM; Cole, CA; Snow, TP; Wang, ZC, 2014
)
2.16
"Uracil is a natural base of RNA but may appear in DNA through two different pathways including cytosine deamination or misincorporation of deoxyuridine 5'-triphosphate nucleotide (dUTP) during DNA replication and constitutes one of the most frequent DNA lesions. "( Uracil within DNA: an actor of antiviral immunity.
Esnault, C; Priet, S; Quérat, G; Sire, J, 2008
)
3.23
"Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (uracil reductase), the enzyme that rapidly catabolizes 5-fluorouracil (5-FU). "( A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil.
Cao, S; Spector, T, 2010
)
1.16
"Uracil is an abundant mutagenic lesion recognized by uracil DNA glycosylase (UDG) in the first step of base excision repair (BER)."( Rotational dynamics of DNA on the nucleosome surface markedly impact accessibility to a DNA repair enzyme.
Hinz, JM; Rodriguez, Y; Smerdon, MJ, 2010
)
1.08
"Uracil was found to be a dominant nucleotide in both poppy pre-miRNA sequences (31.28 +/- 7.06% of total nucleotide composition) and in the first position at the 5' end of the mature poppy miRNAs."( Identification of conserved micro-RNAs and their target transcripts in opium poppy (Papaver somniferum L.).
Dündar, E; Parmaksiz, I; Unver, T, 2010
)
1.08
"Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC). "( Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma.
Chang, AY; de Lima Lopes, G; Dicksey, JS; Palalay, M; Peters, WP, 2011
)
1.16
"Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU). "( Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002
)
1.17
"Eniluracil is an inactivator of dihydropyrimidine dehydrogenase, the first enzyme in the catabolic pathway of 5-fluorouracil (5-FU). "( A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Beale, P; Ertel, P; Judson, I; O'Donnell, A; Punt, CJ; Suttle, AB; Van Maanen, L, 2003
)
1.12
"Uracil in DNA is a deleterious event that may arise either by cytosine deamination or misincorporation of dUTP. "( Uracils as a cellular weapon against viruses and mechanisms of viral escape.
Priet, S; Quérat, G; Sire, J, 2006
)
3.22
"Eniluracil is an effective inactivator of dihydropyrimidine dehydrogenase (DPD). "( A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
Cohen, DP; Czito, BG; Fernando, N; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Morse, MA; Pappas, TN; Petros, WP; Tyler, DS; Yu, D, 2006
)
1.2
"The uracil permease is a multi-spanning membrane protein that follows the secretory pathway to the plasma membrane."( Replacement of Lys by Glu in a transmembrane segment strongly impairs the function of the uracil permease from Saccharomyces cerevisiae.
Chevallier, J; Haguenauer-Tsapis, R; Pinson, B; Urban-Grimal, D, 1995
)
0.99
"Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (DPD), which is the first enzyme in the degradative pathway of systemically administered 5-fluorouracil (5-FU). "( Clinical development of eniluracil: current status.
Hohneker, JA, 1998
)
1.15
"Eniluracil is a novel DPD-inactivator designed to prolong the half-life of 5-FU and provide sustained plasma concentrations of 5-FU with oral dosing."( Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Brockstein, B; Dolan, ME; Haraf, DJ; Humerickhouse, RA; Kies, M; Ratain, MJ; Stenson, K; Sulzen, L; Vokes, EE, 1999
)
1.1
"Uracil permease is a multispan membrane protein that is delivered to the plasma membrane via the secretory pathway."( Only one of the charged amino acids located in membrane-spanning regions is important for the function of the Saccharomyces cerevisiae uracil permease.
Chevallier, J; Pinson, B; Urban-Grimal, D, 1999
)
1.23
"Eniluracil (776C85) is an effective inactivator of dihydropyrimidine dehydrogenase that allows continuous low-dose oral fluorouracil (5-FU) to be given with predicable oral bioavailability. "( Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study.
Barton, CM; Cirkel, DT; de Boer, RH; Hickish, TF; Johnston, SR; Norton, A; O'Brien, ME; Smith, IE, 2000
)
1.19
"Eniluracil is a promising drug, which permits reliable and safe administration of oral 5-FU and has the potential to overcome 5-FU resistance mediated by overexpression of DPD."( Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Kindler, HL; Schilsky, RL, 2000
)
1.35
"Eniluracil is an effective mechanism-based inactivator of dihydropyrimidine dehydrogenase (DPD), the first enzyme in the catabolic pathway of 5-FU."( Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
Baccanari, DP; Cao, S; Davis, ST; Paff, MT; Rustum, YM; Spector, T; Tansik, RL, 2000
)
1.07
"Eniluracil is a potent inactivator of DPD which results in 100% oral bioavailability of 5-FU."( Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001
)
1.09
"Eniluracil is an effective inactivator of dihydropyrimidine dehydrogenase, the initial and rate limiting enzyme in the catabolism of fluorouracil. "( A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer.
Barton, CM; Bonneterre, J; Cirkel, DT; Davidson, NG; Piccart, MJ; Richel, DJ; Skovsgaard, T, 2001
)
1.16

Effects

Uracil-tegafur (UFT) has been reported to have a broad anti-tumor activity in a variety of malignancies including colorectal cancer and breast cancer. Uracil analogues have been applied to treatments of patients with cancer or viral infections.

ExcerptReferenceRelevance
"Uracil has been modified at the 5-position to derive a small library of nucleobase-chromophores which were inspired by green fluorescent protein (GFP). "( Chimeric GFP-uracil based molecular rotor fluorophores.
Cappello, D; Chowdhury, M; Hajjami, M; Hudson, RHE; Turner, JA, 2023
)
2.72
"Uracil analogues have been applied to treatments of patients with cancer or viral infections."( Microbial production of uracil by an isolated Methylobacterium sp. WJ4 using methanol.
Kim, S; Kwon, Y; Lee, J; Lee, W; Oh, BK; Oh, HB; Park, S; Song, I, 2018
)
1.51
"Uracil has abstractable protons at N3 and N1."( pH-dependent UV resonance Raman spectra of cytosine and uracil.
Billinghurst, BE; Loppnow, GR; Oladepo, SA, 2009
)
1.32
"Uracil has been formed under thermal conditions which yield other materials of theoretical prebiochemical significance. "( Synthesis of uracil under conditions of a thermal model of prebiological chemistry.
FOX, SW; HARADA, K, 1961
)
2.05
"Uracil-tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies. "( A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma.
Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Okusaka, T; Ueno, H, 2005
)
2.09
"Eniluracil/5-FU has demonstrated efficacy as monotherapy in patients with a variety of solid tumors when given on a 5 or 28-day dosing schedule."( Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.
Hohneker, J; Levin, J, 2000
)
1.08
"Eniluracil-5-FU has modest antitumor activity and an acceptable safety profile in anthracycline- and taxane-resistant breast cancer. "( Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer.
Colwell, B; Conklin, HS; Frye, D; Graham, M; Hortobagyi, GN; Levin, J; McGuirt, C; Rivera, E; Somerville, M; Sutton, L, 2002
)
1.1
"Uracil-tegafur (UFT) has been reported to have a broad anti-tumor activity in a variety of malignancies including colorectal cancer and breast cancer. "( Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer.
Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002
)
2.09
"Uracil has been shown to cause a strong proliferative response in the urinary bladder epithelium of rats and mice through calculus formation and, consequently, acts as a strong promoter in bladder carcinogenesis. "( Strong promoting activity by uracil on urinary bladder carcinogenesis and a possible inhibitory effect on thyroid tumorigenesis in rats initiated with N-methyl-N-nitrosourea.
Cohen, SM; Garland, EM; Mann, AM; Masui, T, 1989
)
2.01

Actions

Uracil promotes cell surface Rsp5p-dependent ubiquitylation of the permease, signaling its endocytosis and further vacuolar degradation. Uracil is known to cause reversible urolithiasis and to induce papillomatosis in the urinary bladder of F344 rats.

ExcerptReferenceRelevance
"Eniluracil/5-FU/Lv might enable these patients to continue with oral 5-FU rather than switching to the generally less well tolerated intravenous microtubule-interfering agents."( Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.
Burdaeva, O; Chang, JC; Kirby, MG; Rivera, E; Semiglazov, V; Spector, T, 2014
)
1.44
"Uracil was found to enhance pullulan accumulation and the addition time of uracil was crucial to pullulan production."( Effect of uracil on pullulan production by Aureobasidium pullulans CGMCC1234.
Sheng, L; Tong, Q; Zhu, G, 2014
)
1.53
"Uracil promotes cell surface Rsp5p-dependent ubiquitylation of the permease, signaling its endocytosis and further vacuolar degradation."( Direct sorting of the yeast uracil permease to the endosomal system is controlled by uracil binding and Rsp5p-dependent ubiquitylation.
Blondel, MO; Dupré, S; Haguenauer-Tsapis, R; Morvan, J; Urban-Grimal, D; Volland, C, 2004
)
1.34
"Uracil is known to cause reversible urolithiasis and to induce papillomatosis in the urinary bladder of F344 rats. "( Summation effect of uracil on the two-stage and multistage models of urinary bladder carcinogenesis in F344 rats initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Fukushima, S; Masui, T; Mutai, M; Shirai, T; Takahashi, S, 1988
)
2.04

Treatment

Uracil treatments are effective at removing DNA damage. Treatment with uracil DNA-glycosylase produces d(TTTrTTTT), where r = deoxyribose, and d(AAAAGTTprpAAAACAT)

ExcerptReferenceRelevance
"Uracil treatments are effective at removing DNA damage even at concentrations of 0.15 U/µL (as compared to 0.3 U/µL) of ancient DNA extracts."( Development and Optimization of a Silica Column-Based Extraction Protocol for Ancient DNA.
Dalén, L; Danilov, GK; Dehasque, M; Ersmark, E; Kempe Lagerholm, V; Mortensen, P; Pečnerová, P; Vartanyan, S, 2022
)
1.44
"Treatment with uracil DNA-glycosylase produces d(TTTrTTTT), where r = deoxyribose, and d(AAAAGTTprpAAAACAT)."( Synthesis and properties of oligodeoxynucleotides with an AP site at a preselected position.
Chambers, RW; Stuart, GR, 1987
)
0.61

Toxicity

A yeast strain lacking the enzyme uracil DNA glycosylase (Ung1) showed significant protection against the toxic effects of 5-FU. Uracil plus tegafur was shown to be less toxic than the drug alone in all the species.

ExcerptReferenceRelevance
" However it acts toxically on tumor cells though it is not toxic for intact cells so that its action is different as compared to that of cytotoxic agents."( [Toxicity of para-aminobenzhydrazide and its influence on nucleic acid biosynthesis in cultures of normal and tumor cells].
Filov, VA; Onishchuk, FD; Tret'iakov, AV, 1989
)
0.28
" HeLa cells, known to be resistant to the toxic effects of HmdUrd, do not incorporate HmdUrd into their DNA."( Effects of 5-hydroxymethyluracil and 3-aminobenzamide on the repair and toxicity of 5-hydroxymethyl-2'-deoxyuridine in mammalian cells.
Boorstein, RJ; Teebor, GW, 1989
)
0.58
" 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines."( [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988
)
0.27
" In this study, the two types of toxic behaviors and symptoms were observed in UFT, FT-207 and 5-FU."( A nine-month chronic toxicity study of tegafur-uracil mixture (UFT) in dogs.
Ariyoshi, T; Maruden, A; Morita, K; Sutou, H; Takenouchi, T; Yamashita, K, 1988
)
0.53
" All three tumor cell lines were more sensitive to OHUrd than were the FeInt cells, whereas 5-FU was more toxic to the latter."( Selective cytotoxicity of 5-hydroxyuridine for human colon adenocarcinoma cells.
Giovanella, BC; Lockshin, A; Mendoza, JT; Stehlin, JS; Warneke, C,
)
0.13
" While there were minor differences seen in food consumption, water consumption and erythroid parameters between the 3-month and the 12-month studies, it was concluded that there were no adverse effects seen on these parameters nor on body weight, EKG, clinical laboratory studies and organ weights."( Toxicity study of uracil in dogs.
Morita, K; Richter, WR; Spicer, EJ, 1985
)
0.6
" Uracil plus tegafur was shown to be less toxic than the drug alone in all the species, and uracil was found to decrease the toxicity of tegafur."( Effect of coadministration of uracil on the toxicity of tegafur.
Haruno, A; Kunimune, Y; Morita, K; Unemi, N; Yamamoto, J; Yamashita, K; Yoshimura, Y, 1984
)
1.47
" This side effect was also seen after administration of uridine (10 g/sq m) during combination with 5-fluorouracil."( Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Gall, H; Kraal, I; Lankelma, J; Leyva, A; Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1984
)
0.7
" To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU."( Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999
)
0.63
" EMV tested negative for genotoxic activity, and except for decreased feed consumption at the high dose (160 mg/kg/day), with resultant decreases in maternal and fetal body weights, EMV produced no adverse effects in a complete range of reproductive toxicology experiments performed on rats and rabbits."( Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.
Barry, DW; Blum, MR; Borroto-Esoda, K; Endoh, R; Furman, P; Grizzle, TB; Moxham, C; Niwa, T; Painter, GR; Sommadossi, J; Szczech, GM; Yamamoto, M, 2000
)
0.31
" The correlation between pharmacokinetic parameters and toxic effects of UFT was evaluated."( Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
Brown, N; Covington, W; Creaven, PJ; Hayakawa, T; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Lin, SN; Meropol, NJ; Pazdur, R; Rustum, YM, 2000
)
0.82
" The major toxic effects observed were diarrhea and nausea and vomiting."( Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
Brown, N; Covington, W; Creaven, PJ; Hayakawa, T; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Lin, SN; Meropol, NJ; Pazdur, R; Rustum, YM, 2000
)
0.82
" The preliminary findings suggest that determination of plasma levels of 5-FU after oral administration of UFT may help predict subsequent toxic effects."( Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
Brown, N; Covington, W; Creaven, PJ; Hayakawa, T; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Lin, SN; Meropol, NJ; Pazdur, R; Rustum, YM, 2000
)
0.82
" Both products showed no toxic effects even at doses 50 times higher than the LD50 of cylindrospermopsin (10 mg/kg mouse ip)."( Uracil moiety is required for toxicity of the cyanobacterial hepatotoxin cylindrospermopsin.
Banker, R; Carmeli, S; Porat, R; Sukenik, A; Teltsch, B; Werman, M, 2001
)
1.75
" There are no toxic effects of 5-fodUrd on cells defective in thymidine kinase or thymidylate synthetase, suggesting that the toxicity may be caused by 5-fodUrd phosphorylation and subsequent inhibition of thymidylate synthetase."( 5-Formyluracil and its nucleoside derivatives confer toxicity and mutagenicity to mammalian cells by interfering with normal RNA and DNA metabolism.
Bjelland, S; Klungland, A; Matsuda, A; Paulsen, R; Rolseth, V; Seeberg, E; Ueno, Y; Wiik, P; Yamada, Y, 2001
)
0.74
" Microcystin-LR, cylindrospermopsin and lophyrotomin all exhibited toxic effects on the primary rat hepatocytes with 72-h LC(50) of 8, 40 and 560 ng/ml, respectively."( Toxicity and uptake mechanism of cylindrospermopsin and lophyrotomin in primary rat hepatocytes.
Chong, MW; Lam, PK; Seawright, AA; Shaw, GR; Wong, BS, 2002
)
0.31
" It is known to be a potent protein synthesis inhibitor, but there is mounting evidence for genotoxicity and that it metabolizes to even more toxic forms."( Oral toxicity of the cyanobacterial toxin cylindrospermopsin in male Swiss albino mice: determination of no observed adverse effect level for deriving a drinking water guideline value.
Falconer, IR; Humpage, AR, 2003
)
0.32
" In exposed mice the liver is the main target for the toxic effects of CYN."( Cylindrospermopsin-induced protein synthesis inhibition and its dissociation from acute toxicity in mouse hepatocytes.
Burcham, PC; Falconer, IR; Froscio, SM; Humpage, AR, 2003
)
0.32
" raciborskii contained CYN, however, all isolates were toxic to primary rat hepatocytes, human hepatoblastoma (HEP-G2) and human colon adenocarcinoma (CACO-2) cells."( Cylindrospermopsin occurrence in two German lakes and preliminary assessment of toxicity and toxin production of Cylindrospermopsis raciborskii (Cyanobacteria) isolates.
Chorus, I; Eaglesham, GK; Fastner, J; Heinze, R; Humpage, AR; Mischke, U, 2003
)
0.32
" A yeast strain lacking the enzyme uracil DNA glycosylase (Ung1), which excises uracil from the DNA backbone leaving an abasic site, showed significant protection against the toxic effects of 5-FU, a G1/S cell cycle arrest phenotype, and accumulated massive amounts of U/A base pairs in its genome (approximately 4% of T/A pairs were now U/A)."( Linking uracil base excision repair and 5-fluorouracil toxicity in yeast.
Dizdaroglu, M; Jaruga, P; Seiple, L; Stivers, JT, 2006
)
1.05
"Purified cyanobacterial lipopolysaccharide (LPS) was not acutely toxic to three aquatic invertebrates (Artemia salina, Daphnia magna and Daphnia galeata) in immersion trials."( Protection against the toxicity of microcystin-LR and cylindrospermopsin in Artemia salina and Daphnia spp. by pre-treatment with cyanobacterial lipopolysaccharide (LPS).
Codd, GA; Lindsay, J; Metcalf, JS, 2006
)
0.33
" Analysis indicates no adverse effects on litter size, fetal weight, or incidence of anomalies."( The cyanobacterial toxin, cylindrospermopsin, induces fetal toxicity in the mouse after exposure late in gestation.
Chernoff, N; Falconer, IR; Gage, MI; Humpage, AR; Marr, M; Rogers, EH; Zehr, RD, 2007
)
0.34
" Overall, incidences of adverse events (67."( Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
DeFronzo, RA; Fleck, PR; Mekki, Q; Wilson, CA, 2008
)
0.35
"Cyanobacteria produce a diverse array of toxic or otherwise bioactive compounds that pose growing threats to human and environmental health."( Toxicity of cylindrospermopsin, and other apparent metabolites from Cylindrospermopsis raciborskii and Aphanizomenon ovalisporum, to the zebrafish (Danio rerio) embryo.
Berry, JP; Gibbs, PD; Saker, ML; Schmale, MC, 2009
)
0.35
" Our results showed no correlation between toxic phenotype and phylogenetic association in the Australian strains."( Toxicity phenotype does not correlate with phylogeny of Cylindrospermopsis raciborskii strains.
Fuentes-Valdés, JJ; Méndez, MA; Murillo, AA; Soto-Liebe, K; Stucken, K; Vásquez, M, 2009
)
0.35
" Overall, adverse events (AEs) observed with alogliptin were not substantially different from those observed with placebo."( Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Ellis, GC; Fleck, PR; Mekki, Q; Nauck, MA; Wilson, CA, 2009
)
0.35
"Alogliptin is an effective and safe treatment for type 2 diabetes when added to metformin for patients not sufficiently controlled on metformin monotherapy."( Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Ellis, GC; Fleck, PR; Mekki, Q; Nauck, MA; Wilson, CA, 2009
)
0.35
" Short-term exposure of C3A cells to CYN (1-6 h) was shown to induce cytotoxicity at 24 h despite a washout and recovery incubation, demonstrating the protracted and apparently irreversible nature of CYN's toxic effects."( Cytotoxicity screening for the cyanobacterial toxin cylindrospermopsin.
Fanok, S; Froscio, SM; Humpage, AR, 2009
)
0.35
" The incidences of overall adverse events and hypoglycemia were similar across treatment groups, but cardiac events occurred more often with active treatment than placebo."( Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Fleck, PR; Mekki, Q; Pratley, RE; Reusch, JE; Wilson, CA, 2009
)
0.35
" Our results confirmed that longterm postoperative therapy with UFT alone was feasible, provided that early adverse events are carefully monitored."( [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Noguchi, S; Taguchi, T, 2009
)
0.61
"EP-UFT with lower UFT doses and without leucovorin support is a safe and effective regimen as first -line treatment of MGC."( Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients.
Alacacioglu, A; Meydan, N; Oztop, I; Somali, I; Tarhan, MO; Yilmaz, U,
)
0.13
"The presence of a toxic strain of a fine filamentous cyanobacterium belonging to the Oscillatorialean family Pseudanabaenacea was detected during a survey of cyanobacterial taxa associated with the presence of cylindrospermopsin in dams in Central Queensland (Australia)."( Novel toxic effects associated with a tropical Limnothrix/Geitlerinema-like cyanobacterium.
Bernard, C; Campbell, R; Fabbro, L; Froscio, S; Humpage, A; Monis, P, 2011
)
0.37
" Adverse effects of CYN were monitored up to 7 weeks post-dosing by clinical examination, histopathology, biochemistry and gene expression."( Toxicity and recovery in the pregnant mouse after gestational exposure to the cyanobacterial toxin, cylindrospermopsin.
Bradfield, CA; Chernoff, N; Gage, MI; Jaskot, RH; Liu, Y; Malarkey, DE; Richards, JH; Rogers, EH; Rosen, MB; Schmid, JE; Wood, CR; Zehr, RD, 2011
)
0.37
" Safety endpoints were the occurrence of adverse events, vital sign measurements, physical examination and ECG findings, and laboratory test results recorded over the entire 52-week period."( Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
Fujita, T; Hirayama, M; Hiroi, S; Kaku, K; Seino, Y, 2011
)
0.37
" The incidence of adverse events with alogliptin over 52 weeks was not dose-dependent and was lower than with voglibose."( Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
Fujita, T; Hirayama, M; Hiroi, S; Kaku, K; Seino, Y, 2011
)
0.37
"The fluoropyrimidines are commonly used in chemotherapeutic cancer medicine, but many patients still experience severe adverse side effects from these drugs."( Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation.
Caroti, C; Cassola, G; D'Amico, M; Di Maria, E; Faravelli, F; Forzano, F; Fucile, C; Giorgio, E; Marini, V; Martelli, A; Mattioli, F; Parodi, MI; Uliana, V, 2011
)
0.37
" Therefore, it has been demonstrated that CYN can induce toxic effects in Caco-2 cells in a time-concentration dependent manner."( Biochemical and pathological toxic effects induced by the cyanotoxin Cylindrospermopsin on the human cell line Caco-2.
Cameán, AM; Gutiérrez-Praena, D; Jos, A; Moreno, FJ; Pichardo, S, 2012
)
0.38
" Treatment-emergent adverse events (AE) were reported by 62."( Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.
Bloom, BJ; Gupta, P; Ishaq, S; Mebus, CA; Park, W; Stock, TC; Wang, X; Wei, N, 2012
)
0.38
" The overall incidence of adverse events (AEs) were 80% in S-1 and 74% in UFT/LV."( Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial.
Boku, N; Endo, T; Ikejiri, K; Kameoka, S; Kinugasa, Y; Kotake, K; Matsubara, Y; Mochizuki, H; Mochizuki, I; Nakamoto, Y; Shinozaki, H; Sugihara, K; Takagane, A; Takahashi, K; Takahashi, Y; Takii, Y; Takiuchi, H; Tomita, N; Watanabe, M; Watanabe, T, 2012
)
0.38
" The primary endpoint during the long-term extension phase was adverse events."( Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Hirayama, M; Hiroi, S; Kaku, K; Miyata, Y; Seino, Y, 2012
)
0.38
" Incidences of adverse effects were comparable between groups, with no increases in hypoglycaemia."( Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Hirayama, M; Hiroi, S; Kaku, K; Miyata, Y; Seino, Y, 2012
)
0.38
"5 and 25 mg once daily was safe and effective when added to metformin (500 or 750 mg/day) in Japanese patients with inadequately controlled type 2 diabetes on metformin alone."( Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Hirayama, M; Hiroi, S; Kaku, K; Miyata, Y; Seino, Y, 2012
)
0.38
"SACURA trial is a multicenter randomized phase III study which aims to evaluate the superiority of 1-year adjuvant treatment with UFT to observation without any adjuvant treatment after surgery for stage II colon cancer in a large population, and to identify "high-risk factors of recurrence/death" in stage II colon cancer and predictors of efficacy and adverse events of the chemotherapy."( Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer.
Ishiguro, M; Ishikawa, T; Kanemitsu, Y; Kotake, K; Matsui, S; Mochizuki, H; Shimada, Y; Sugihara, K; Takahashi, K; Teramukai, S; Tomita, N; Ueno, H; Uetake, H; Watanabe, M, 2012
)
0.38
"We evaluated the incidence of CV events in patients treated with alogliptin, placebo or comparator antihyperglycaemic drugs in the clinical trial database for alogliptin using the composite major adverse cardiovascular event (MACE) endpoints of CV death, non-fatal myocardial infarction and non-fatal stroke."( Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
Fleck, P; Hisada, M; Menon, V; Munsaka, M; Pratley, R; White, WB; Wilson, C, 2013
)
0.39
"3 and 3 μg/kg) during pregnancy causes toxic effects and impairs gestation in rats."( Oral exposure to cylindrospermopsin in pregnant rats: reproduction and foetal toxicity studies.
Araújo Moura Lemos, TM; Barbosa, PF; Caldas de Queiroz, E; Costa de Arruda, AC; Kujbida, P; Matias de Lima Costa, HT; Oliveira, CN; Pinto, E; Schwarz, A; Sibaldo de Almeida, C, 2013
)
0.39
" The safety endpoints consisted of the incidence of hypoglycemia and other adverse events."( [The design and baseline characteristics of a phase III study to evaluate the efficacy and safety of alogliptin versus placebo in type 2 diabetes mellitus in Mainland China].
Bu, RF; Gu, W; Han, P; Ji, QH; Jiang, ZS; Lei, MX; Li, CJ; Li, L; Li, WH; Li, XF; Li, XJ; Li, ZF; Liu, JD; Liu, XM; Liu, Y; Liu, ZM; Lu, JM; Lü, XF; Pan, CY; Peng, YD; Qu, S; Shi, BY; Song, QH; Xu, XJ; Xue, YM; Yan, L; Yang, JK; Zeng, JE; Zheng, BZ, 2013
)
0.39
" Alogliptin appears to be weight neutral and is relatively well tolerated with few adverse effects."( Alogliptin: safety, efficacy, and clinical implications.
Cole, SW; Marino, AB, 2015
)
0.42
"Alogliptin alone or in combination with other antidiabetic agents has shown a significant reduction in HbA1c while remaining safe and tolerable."( Alogliptin: safety, efficacy, and clinical implications.
Cole, SW; Marino, AB, 2015
)
0.42
"8% and grade 3 or higher adverse events occurred in 12."( A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
Hasegawa, K; Ijichi, M; Kawasaki, S; Kokudo, N; Koyama, H; Makuuchi, M; Miyagawa, S; Oba, M; Saiura, A; Takayama, T; Teruya, M; Yamamoto, J; Yoshimi, F, 2014
)
0.72
" The overall incidence of adverse events (AEs) was 75."( Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
Baba, H; Hamada, C; Kakeji, Y; Katsumata, K; Koda, K; Kodaira, S; Kondo, K; Matsuoka, J; Morita, T; Nishimura, G; Sadahiro, S; Saji, S; Sasaki, K; Sato, S; Tsuchiya, T; Usuki, H; Yamaguchi, Y, 2014
)
0.66
"Oral UFT plus leucovorin given by either dosage schedule is a very safe regimen for adjuvant chemotherapy."( Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
Baba, H; Hamada, C; Kakeji, Y; Katsumata, K; Koda, K; Kodaira, S; Kondo, K; Matsuoka, J; Morita, T; Nishimura, G; Sadahiro, S; Saji, S; Sasaki, K; Sato, S; Tsuchiya, T; Usuki, H; Yamaguchi, Y, 2014
)
0.66
"This review considers the pharmacokinetic profile, adverse effects and drug interactions of DPP-4 inhibitors."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" However, DPP-4 inhibitors have certain differences in their pharmacokinetic properties that may be associated with different clinical effects and adverse event profiles."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
"Cylindrospermopsin (CYN) is a toxin produced by a variety of fresh-water cyanobacterial species worldwide and induces significant adverse effects in both livestock and humans."( The course of toxicity in the pregnant mouse after exposure to the cyanobacterial toxin cylindrospermopsin: clinical effects, serum chemistries, hematology, and histopathology.
Brix, A; Chernoff, N; Gage, MI; Hill, D; Malarkey, DE; Rogers, EH; Schmid, JE; Travlos, GS; Zehr, RD, 2014
)
0.4
"Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment."( Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy.
Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014
)
0.76
" Incidences of adverse effects were comparable between groups, with no relevant increases in hypoglycemia or weight gain seen."( Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase.
Kaku, K; Kanoo, T; Katou, M; Mori, M; Seino, Y, 2014
)
0.4
" The obtained results indicate that CYN is able to exert a wide range of adverse effects, including oxidative stress and genotoxicity in fish leucocytes."( Cylindrospermopsin induces oxidative stress and genotoxic effects in the fish CLC cell line.
Rymuszka, A; Sieroslawska, A, 2015
)
0.42
" Adverse events included eye stye, insomnia, and pain from an infiltrated intravenous line."( Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ, 2015
)
0.42
"The directed application of the normal nucleobase uracil to the squamous cells of the oral mucosa and palms and soles together with the delivery of the normal nucleobase adenine to the columnar cells of the GI tract may enable the safe delivery of higher 5FU dose intensity."( Differential nucleobase protection against 5-fluorouracil toxicity for squamous and columnar cells: implication for tissue function and oncogenesis.
Albrecht, P; Ford, JP; Kamerow, H; Mandetta, D; Thompson, JT; Vanden Heuvel, JP, 2015
)
0.92
" The overall incidence rates of treatment-emergent adverse events were similar among the treatment groups."( Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study.
Igeta, M; Kaku, K; Katou, M; Ohira, T; Sano, H, 2015
)
0.42
" Rates of discontinuation due to adverse events (0-1% and 8-11%, respectively, p<0."( Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Arama, V; Campbell, A; Caruntu, FA; Conway, B; Curescu, M; Dalgard, O; Dore, GJ; Fuster, F; Ghesquiere, W; Greenbloom, S; Janczewska, E; Kapoor, M; Knysz, B; Liu, X; Liu, Y; Luo, Y; Mazur, W; Motoc, A; Podsadecki, T; Sasadeusz, J; Shaw, D; Skoien, R; Soza, A; Streinu-Cercel, A; Sullivan, D; Tornai, I, 2016
)
0.43
" OBV/PTV/r+DSV±RBV was associated with a generally better mental and physical health, more favorable tolerability, and lower rates of treatment discontinuation due to adverse events."( Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Arama, V; Campbell, A; Caruntu, FA; Conway, B; Curescu, M; Dalgard, O; Dore, GJ; Fuster, F; Ghesquiere, W; Greenbloom, S; Janczewska, E; Kapoor, M; Knysz, B; Liu, X; Liu, Y; Luo, Y; Mazur, W; Motoc, A; Podsadecki, T; Sasadeusz, J; Shaw, D; Skoien, R; Soza, A; Streinu-Cercel, A; Sullivan, D; Tornai, I, 2016
)
0.43
"The applicability of Density Functional Theory (DFT) based descriptors for the development of quantitative structure-toxicity relationships (QSTR) is assessed for two different series of toxic aromatic compounds, viz."( Toxicity prediction of PHDDs and phenols in the light of nucleic acid bases and DNA base pair interaction.
Mondal Roy, S; Roy, DR; Sahoo, SK, 2015
)
0.42
" In particular, adverse events (AEs) that have been of interest for the DPP-4 class of drugs, such as the risk of major cardiovascular (CV) events and acute pancreatitis, will be investigated in detail."( Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
Seino, Y; Yabe, D, 2016
)
0.43
" The most common grade 3 or 4 adverse events were neutropenia (41."( Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Bando, H; Doi, T; Fukuoka, S; Kawazoe, A; Kojima, T; Kotani, D; Kuboki, Y; Ohtsu, A; Okamoto, W; Shitara, K; Yoshino, T, 2016
)
0.43
"Cylindrospermopsin (CYN) is a potent toxic alkaloid produced by a number of cyanobacteria frequently found in lakes and reservoirs used as drinking water sources."( Ozonation of Cylindrospermopsin (Cyanotoxin): Degradation Mechanisms and Cytotoxicity Assessments.
Dionysiou, DD; Jia, A; Merel, S; O'Shea, KE; Snyder, SA; Song, W; Yan, S, 2016
)
0.43
" The percentage of subjects who experienced all adverse events including hypoglycemia with alogliptin were comparable to those with placebo."( [Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
Bu, R; Gu, W; Han, P; Ji, Q; Jiang, Z; Lei, M; Li, C; Li, L; Li, W; Li, X; Li, Z; Liu, J; Liu, X; Liu, Y; Liu, Z; Lu, J; Lyu, X; Pan, C; Peng, Y; Qu, S; Shi, B; Song, Q; Xu, X; Xue, Y; Yan, L; Yang, J; Zeng, J; Zheng, B, 2015
)
0.42
" Major adverse events were neutropenia, leukopenia, anemia, and nausea."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43
" Regarding safety, adverse events and serious adverse events were more frequently reported in patients taking concomitant ARAs, though baseline population differences may have played a role."( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML, 2016
)
0.43
" The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%)."( Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
Akashi, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Kusaba, H; Makiyama, A; Matsushita, Y; Mitsugi, K; Shibata, Y; Shimokawa, HK; Shirakawa, T; Tamura, S, 2016
)
0.43
" A similar percentage of patients experienced drug-related, treatment-emergent adverse events in the alogliptin and placebo arms."( Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Chan, J; Han, P; Hsieh, AT; Ji, Q; Li, C; Li, W; Lu, J; Pan, C; Yang, J; Zeng, J, 2017
)
0.46
"8% of the patients experienced at least one adverse event for monotherapy, 87."( Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study.
Inagaki, N; Kaku, K; Kuroda, S; Sano, H; Seki, Y, 2016
)
0.43
" Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95."( Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016
)
0.43
" This postmarketing surveillance study investigated expected and unexpected adverse drug reactions (ADRs) of TAS-102 in clinical practice in the first 6 months after market launch."( TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study.
Fujita, N; Furuta, T; Hara, N; Katori, J; Muro, K; Uetake, H; Yoshino, T, 2016
)
0.43
" Safety outcomes were presented by the incidence of adverse events."( Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
Chamorro-de-Vega, E; Collado Borrell, R; Escudero-Vilaplana, V; Fernandez-Llamazares, CM; Gimenez-Manzorro, A; Herranz, A; Ibañez-Garcia, S; Lallana Sainz, E; Lobato Matilla, E; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Marzal-Alfaro, M; Ribed, A; Rodriguez-Gonzalez, CG; Romero Jimenez, RM; Sanjurjo, M; Sarobe Gonzalez, C, 2016
)
0.43
" Adverse events occurred in 91."( Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
Chamorro-de-Vega, E; Collado Borrell, R; Escudero-Vilaplana, V; Fernandez-Llamazares, CM; Gimenez-Manzorro, A; Herranz, A; Ibañez-Garcia, S; Lallana Sainz, E; Lobato Matilla, E; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Marzal-Alfaro, M; Ribed, A; Rodriguez-Gonzalez, CG; Romero Jimenez, RM; Sanjurjo, M; Sarobe Gonzalez, C, 2016
)
0.43
" Drug-related adverse events (AEs) and grade ≥3 AEs were 23 (100%) and 10 (43."( Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016
)
0.43
" Adverse events occurred in 151 (72."( Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D, 2016
)
0.43
"Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real-life clinical setting in Hong Kong."( Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF, 2017
)
0.46
" The overall frequency of adverse events was similar among the groups."( Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes.
Kaku, K; Katou, M; Kinugawa, Y; Nishiyama, Y; Sumino, S, 2017
)
0.46
" Details of serious adverse events (SAEs) were recorded."( Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J, 2017
)
0.46
" Other correlates with adverse events of clinical importance included concomitant ribavirin treatment, sex, race, and presence of cirrhosis, consistent with previous observations."( Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
Awni, W; DaSilva-Tillmann, B; Dutta, S; Lin, CW; Liu, W; Menon, R; Podsadecki, T; Shulman, N, 2017
)
0.46
" Clinical and laboratory adverse events (AEs) were recorded from baseline to FU12."( Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M, 2017
)
0.46
" The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pre-treatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs) on treatment."( Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017
)
0.46
" Baseline demographic, clinical and laboratory information, on-treatment biochemical, virological and haematological indices and details on serious adverse events were collected locally."( Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017
)
0.46
"Cyanobacterial toxins, particularly microcystins (MCs) and cylindrospermopsin (CYN), are responsible for toxic effects in humans and wildlife."( Potential Use of Chemoprotectants against the Toxic Effects of Cyanotoxins: A Review.
Cameán, AM; Campos, A; Gutiérrez-Praena, D; Guzmán-Guillén, R; Jos, Á; Pichardo, S; Prieto, AI; Puerto, M; Vasconcelos, V, 2017
)
0.46
" The number and percentage of patients with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs consistent with hepatic decompensation were reported."( Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H, 2017
)
0.46
" Data were analyzed to assess the on-treatment and off-therapy HCV viral load and on-treatment adverse events."( Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC, 2018
)
0.48
" Expert opinion: Clinical trial data to date suggest that trelagliptin is a safe and efficacious medication with a similar safety profile to once-daily DPP-4 inhibitors, and to the once-weekly DPP-4 inhibitor, omarigliptin."( Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients.
Kaku, K, 2017
)
0.46
" Adverse events were reported in 42."( Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study.
Inagaki, N; Kaku, K; Kuroda, S; Sano, H; Seki, Y, 2018
)
0.48
"02), while it increased the risk of serious adverse events (p = 0."( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.
Abdel-Daim, MM; Abushouk, AI; Ahmed, H; Loutfy, SA; Menshawy, A; Mohamed, A; Negida, A, 2017
)
0.46
" Integrated data from a larger group of mCRC patients receiving trifluridine/tipiracil at the recommended starting dose (group 1) and nonintegrated data on serious adverse events (SAEs) representing all clinical experience with trifluridine/tipiracil as of the data cutoff date (group 3) are also summarized."( Integrated safety summary for trifluridine/tipiracil (TAS-102).
Bebeau, P; Bendell, JC; Buscaglia, M; Falcone, A; Kopetz, S; Mayer, RJ; Ohtsu, A; Van Cutsem, E; Yoshino, T, 2018
)
0.48
" The overall incidence of any Grade adverse events (AEs) were 91."( Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Aiba, K; Baba, H; Boku, N; Ishiguro, M; Itabashi, M; Kotake, K; Kunieda, K; Kusumoto, T; Maeda, A; Mochizuki, I; Morita, S; Okabe, M; Ota, M; Sakamoto, Y; Sugihara, K; Sunami, E; Takahashi, K; Tomita, N; Yamauchi, J; Yoshida, K, 2018
)
0.69
" While being generally safe, they cause numerous adverse effects including induction of hyperactivity of urinary bladder and intestines affecting quality of patients life."( Specific inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia gravis treatment.
Ilyin, VI; Kharlamova, AD; Lenina, OA; Nikolsky, EE; Nurtdinov, AR; Petrov, KA; Sitdykova, ME; Zueva, IV, 2018
)
0.48
" Safety outcomes were based on the incidence of adverse events."( Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
Chamorro-de-Vega, E; De Lorenzo-Pinto, A; Escudero-Vilaplana, V; Gimenez-Manzorro, A; Herranz-Alonso, A; Iglesias-Peinado, I; Rodriguez-Gonzalez, CG; Sanjurjo Saez, M, 2018
)
0.48
" Adverse events were recorded in 78."( Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
Chamorro-de-Vega, E; De Lorenzo-Pinto, A; Escudero-Vilaplana, V; Gimenez-Manzorro, A; Herranz-Alonso, A; Iglesias-Peinado, I; Rodriguez-Gonzalez, CG; Sanjurjo Saez, M, 2018
)
0.48
"The simplified regimen of OBV/PTV/r+DSV administered for 12 weeks is effective and safe in patients with chronic HCV genotype 1b infection and compensated cirrhosis."( Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
Chamorro-de-Vega, E; De Lorenzo-Pinto, A; Escudero-Vilaplana, V; Gimenez-Manzorro, A; Herranz-Alonso, A; Iglesias-Peinado, I; Rodriguez-Gonzalez, CG; Sanjurjo Saez, M, 2018
)
0.48
" Direct-acting antiviral (DAA) drug regimens are safe and highly effective, allowing administration of treatment also in elderly."( Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Bataga, S; Brisc, C; Caruntu, FA; Chiriac, S; Cijevschi Prelipcean, C; Curescu, M; Gheorghe, L; Girleanu, I; Goldis, A; Iacob, S; Miftode, E; Mihai, C; Preda, C; Rogoveanu, I; Singeap, AM; Sporea, I; Stanciu, C; Stefanescu, G; Trifan, A, 2017
)
0.46
" This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate."( Fluoropyrimidine-induced cardiotoxicity.
Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D, 2018
)
0.48
" Our aim was to analyze the characteristics associated with the presence of adverse events in patients receiving this antiviral regimen, with ribavirin in cirrhotic patients."( Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin.
Calina, OC; Hristea, A; Jipa, RE; Manea, ED; Olariu, C; Stefan, I,
)
0.13
" We recorded 201 adverse events in 98 (71."( Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin.
Calina, OC; Hristea, A; Jipa, RE; Manea, ED; Olariu, C; Stefan, I,
)
0.13
"We found a high number of adverse events, but most of them were mild or moderate and only one quarter of them required medical intervention."( Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin.
Calina, OC; Hristea, A; Jipa, RE; Manea, ED; Olariu, C; Stefan, I,
)
0.13
" The Grade 3 or worst adverse event that was experienced was neutropenia."( [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
Arakawa, S; Asano, Y; Horiguchi, A; Imaeda, Y; Isetani, M; Ishihara, S; Ito, M; Ito, R; Kamio, K; Kawabe, N; Kawai, T; Nagata, H; Shimizu, K; Tomishige, H; Yasuoka, H, 2018
)
0.48
" As such, we assessed disproportionate reporting of major adverse cardiac events (MACE) among reports for DPP-4i submitted to the FDA Adverse Event Reporting System (FAERS) from 2006 to 2015."( Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB, 2018
)
0.48
"3 million adverse event reports, 13."( Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB, 2018
)
0.48
") route of administration and confirmed this pattern of toxicity with changes in liver enzyme activities and histopathology consistent with hepatic injury and adverse renal effects."( Cylindrospermopsin toxicity in mice following a 90-d oral exposure.
Chernoff, N; Chorus, I; Diggs, DL; Hill, DJ; Huang, H; King, D; Lang, JR; Le, TT; Schmid, JE; Travlos, GS; Whitley, EM; Wilson, RE; Wood, CR, 2018
)
0.48
"Patients who suffered any adverse event (AE) were 74/240 (30."( Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL, 2018
)
0.48
"Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65."( Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL, 2018
)
0.48
" Primary endpoints were HbA1c change from baseline to the end of the DB phase and adverse events (AEs)."( Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study.
Ishida, K; Kaku, K; Kuroda, S; Umeda, Y, 2018
)
0.48
"The work experimentally confirms the metyluracyl influence on repair shortening of the small intestine tissue damaged by cyclophosphamide toxic effects by morphological and morphometric methods of investigation."( MORPHOLOGICAL FOUNDATION OF METHYLURACYL APPLICATION FOR CORRECTION OF CYCLOPHOSPHAMIDE TOXIC EFFECT ON RATS SMALL INTESTINE TISSUES.
Bondarchuk, AO, 2016
)
0.43
" The other two patients reported only grade 1 adverse effects."( Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.
Giménez-Manzorro, A; Herranz-Alonso, A; Matilla-Peña, A; Revuelta-Herrero, JL; Sanjurjo-Sáez, M, 2018
)
0.48
"The concurrent use of OBV/PTV/r+DSV with sorafenib was considered safe and effective."( Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.
Giménez-Manzorro, A; Herranz-Alonso, A; Matilla-Peña, A; Revuelta-Herrero, JL; Sanjurjo-Sáez, M, 2018
)
0.48
" However, information about the rate of adverse events (AEs) across different DAA regimens is limited."( Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N, 2018
)
0.48
" Overall, no adverse events other than neutropenia were noted."( Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer.
Narihiro, S; Ohtsu, M; Okamoto, T; Ryu, S; Shimoyama, Y; Suwa, K; Ushigome, T; Yanaga, K,
)
0.13
"0%) had at least 1 adverse event leading to study discontinuation."( Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Bebeau, P; Becerra, C; Rosen, L; Rudek, MA; Saif, MW; Shepard, DR; Sun, W; Winkler, R; Yamashita, F, 2019
)
0.51
" Sustained virologic response at post-treatment Week 12 (SVR12), adverse events (AEs) and comedication management were assessed for patients initiating treatment before 1 June 2017."( Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studi
Back, D; Bondin, M; Bourgeois, S; Buggisch, P; Charafeddine, M; Crown, E; Curescu, M; Dorr, P; Ferenci, P; Flisiak, R; Kleine, H; Larrey, D; Marra, F; Norris, S, 2019
)
0.51
" These toxic secondary metabolites are classified as hepatotoxins and cytotoxin, respectively."( Neurotoxicity induced by microcystins and cylindrospermopsin: A review.
Cameán, AM; Gutiérrez-Praena, D; Guzmán-Guillén, R; Hinojosa, MG; Jos, A; Prieto, AI, 2019
)
0.51
" However, ribavirin is associated with adverse events that can limit its use."( Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Bank, L; Bernstein, D; Epstein, M; Krishnan, P; Lucey, MR; Martinez, M; Nelson, DR; Pockros, PJ; Polepally, AR; Poordad, F; Ravendhran, N; Reindollar, R; Sedghi, S; Trinh, R; Unnebrink, K, 2019
)
0.51
"1% both) were the most frequent adverse events."( Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020
)
0.56
" The patients were evaluated in respect of demographic, clinical and virological data, sustained virologic response (SVR) and adverse events."( [EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN PATIENTS WITH HCV 1B GENOTYPE INFECTION: REAL WORLD DATA].
Skorokhodova, N; Tsarova, O; Zhyvytsia, D, 2019
)
0.51
" We collected data on on-treatment adverse events (AEs), severe AEs, and laboratory abnormalities."( Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Aoufi-Rabih, S; Dixit, V; Fabrizi, F; Garcia-Agudo, R; Mendizabal, M; Ridruejo, E; Silva, M,
)
0.13
" The most common grade ≥ 3 adverse events in trifluridine-tipiracil groups in Phase II and III trials were neutropenia, anemia, and leukopenia."( The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan, BM; Hochster, HS; Lenz, HJ, 2019
)
0.51
" In the double-blind phase, the incidence of treatment-emergent adverse events (TEAEs) was 72."( Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study.
Achira, M; Ishida, K; Kaku, K; Shimizu, K; Umeda, Y, 2020
)
0.56
"7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision."( Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ, 2019
)
0.51
" Direct-acting antiviral therapy is efficacious and safe even in patients with advanced liver disease and/ or previous virological failure; Model-for-End-Liver-Disease <10 and alanine aminotransferase reduction during therapy were found to be reliable predicting markers of sustained-virological-response."( Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V, 2019
)
0.51
"Eutrophication of freshwater bodies increases the occurrence of toxic cyanobacterial blooms."( Adverse effect of cylindrospermopsin on embryonic development in zebrafish (Danio rerio).
Chen, G; Han, L; Hu, T; Wang, L; Wang, Q; Xiao, G, 2020
)
0.56
"Although triiodothyronine (T3) induces several beneficial effects on lipid metabolism, its use is hampered by toxic side-effects, such as tachycardia, arrhythmia, heart failure, bone and muscle catabolism and mood disturbances."( Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.
Bellusci, L; Chiellini, G; Columbano, A; D'Amore, VM; Gul, S; Kowalik, MA; La Pietra, V; Marinelli, L; Novellino, E; Perra, A; Rapposelli, S; Runfola, M; Sestito, S, 2020
)
0.56
" Rates of adverse events (AEs) in the patients was 59."( Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çelen, MK; Çelik, İ; Demirtürk, N; Ersöz, G; Karakeçili, F; Kınıklı, S; Mıstık, R; Şimşek, F; Türker, N; Turkish Society Of Clinical Microbiology And Infectious Diseases, TSGFVHOT; Ural, O; Yıldız, O; Zararsız, G, 2020
)
0.56
" Symptomatic hypoglycemia, pancreatitis, skin disorders of non-extrinsic origin, severe infections, and cancer were collected as major adverse events (AEs)."( Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Abiko, A; Araki, E; Fujimoto, S; Fujiwara, M; Hayashi, M; Inagaki, N; Kadowaki, T; Katagiri, H; Miyoshi, H; Nakamura, J; Naruse, K; Nishimura, R; Okada, Y; Shikata, K; Shimada, A; Shimomura, I; Tanizawa, Y; Ueki, K; Watada, H; Yamada, Y; Yamazaki, T, 2021
)
0.62
"Alogliptin as a representative of DPP-4 inhibitors was safe and durably efficacious when used alone or with other OHAs for patients with type 2 diabetes in the real world setting."( Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Abiko, A; Araki, E; Fujimoto, S; Fujiwara, M; Hayashi, M; Inagaki, N; Kadowaki, T; Katagiri, H; Miyoshi, H; Nakamura, J; Naruse, K; Nishimura, R; Okada, Y; Shikata, K; Shimada, A; Shimomura, I; Tanizawa, Y; Ueki, K; Watada, H; Yamada, Y; Yamazaki, T, 2021
)
0.62
"Harmful cyanobacterial blooms are increasing and becoming a worldwide concern as many bloom-forming cyanobacterial species can produce toxic metabolites named cyanotoxins."( In Vivo and In Vitro Toxicity Testing of Cyanobacterial Toxins: A Mini-Review.
Lima, ST; Metcalf, JS; Nowruzi, B; Porzani, SJ, 2021
)
0.62
" The primary endpoints were change in HbA1c versus baseline, and the incidence of gastrointestinal adverse events (AEs)."( Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi
Gao, B; Gao, W; Ji, Q; Wan, H; Xu, F; Zhang, X; Zhou, R, 2022
)
0.72
" Although the main target organ is the liver, recent studies indicate that CYN has potential toxic effects on the nervous system, both in vitro and in vivo."( Cytotoxicity and Effects on the Synapsis Induced by Pure Cylindrospermopsin in an E17 Embryonic Murine Primary Neuronal Culture in a Concentration- and Time-Dependent Manner.
Cameán, AM; Hinojosa, MG; Jos, Á; Muñoz-Castro, C; Prieto, AI; Sánchez-Mico, MV; Vitorica, J, 2022
)
0.72
" In terms of safety, we monitored the development of adverse reactions, liver cytolysis, cholestasis, and hematologic disorders."( A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Bacinschi, X; Gales, L; Haineala, B; Iliescu, L; Mercan, A; Popescu, GC; Rodica, A; Serban, D; Toma, L; Zgura, A, 2022
)
0.72
" Adverse events of any grade were reported in 58% of patients."( Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Arrichiello, G; Ciardiello, D; Ciardiello, F; De Falco, V; Facchini, G; Famiglietti, V; Incoronato, P; Laterza, MM; Martinelli, E; Martini, G; Nacca, V; Napolitano, R; Napolitano, S; Nicastro, A; Paragliola, F; Perrone, A; Suarato, G; Troiani, T, 2022
)
0.72
" We compared the antibody titers of SARS-CoV-2 vaccines and the adverse events between patients who received adjuvant UFT and patients who did not."( Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur-uracil as postoperative adjuvant chemotherapy.
Doi, T; Funakoshi, Y; Hojo, W; Hokka, D; Maniwa, Y; Minami, H; Mitsui, S; Nishikubo, M; Ohji, G; Sakai, H; Tanaka, Y; Yakushijin, K, 2023
)
1.14
" The prevalence of adverse events did not differ significantly between the groups, and no severe adverse events occurred."( Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur-uracil as postoperative adjuvant chemotherapy.
Doi, T; Funakoshi, Y; Hojo, W; Hokka, D; Maniwa, Y; Minami, H; Mitsui, S; Nishikubo, M; Ohji, G; Sakai, H; Tanaka, Y; Yakushijin, K, 2023
)
1.14
" Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13."( Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M, 2023
)
0.91
" In the overall population, the most common grade 3 or higher treatment-related adverse events were neutropenia (37%), anemia (32%) leukopenia (20%), thrombocytopenia (8%), and anorexia (7%)."( Safety and Efficacy of Trifluridine/Tipiracil Administered After Anti-PD-1 Therapies for Advanced Gastric Cancer.
Demachi, K; Kawazoe, A; Kotani, D; Nakamura, H; Okunaka, M; Shitara, K,
)
0.13
" No unexpected adverse events were observed in both groups."( Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Kawazoe, A; Kotani, D; Kuboki, Y; Mishima, S; Nakamura, H; Nakamura, Y; Okunaka, M; Shitara, K, 2023
)
0.91

Pharmacokinetics

The main purpose of the present review article was to shed light on the different 5-fluorouracil (5-FU) prodrugs. It also underlined their respective pharmacological features in terms of metabolic activation, dihydropyrimidine dehydrogenase inhibition, pharmacokinetic profile and biomodulation ability.

ExcerptReferenceRelevance
"Methods for pharmacokinetic modulation of the plasma 5-fluorouracil (5-FU) level to increase antitumor activity during continuous venous infusion (CVI) of low doses of 5-FU were examined in Yoshida sarcoma-bearing rats."( Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.
Fujii, S; Fukushima, M; Shimamoto, Y; Shirasaka, T, 1989
)
0.78
" administration followed first-order kinetics with a half-life of approximately 36 min."( Benzylacyclouridine. Pharmacokinetics, metabolism and biochemical effects in mice.
Darnowski, JW; Handschumacher, RE, 1988
)
0.27
"A clinical and pharmacokinetic investigation of prolonged administration of high-dose uridine was performed in seven patients with advanced-stage cancer."( Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity.
Kraal, I; Leyva, A; Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1986
)
0.27
" Pharmacokinetic study after single oral administration of 300 to 1200 mg of UFT-E was carried out in cancer patients measuring tagafur, uracil and 5-FU levels in serum, normal tissue and tumor tissue using HPLC and GC-mass."( [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Fujii, S; Hoshino, A; Kamiya, O; Kimura, K; Kojima, T; Nagata, K; Ohara, K; Sugihara, T; Suzuki, M; Yamada, M, 1983
)
0.72
" Uridine plasma decay curves were biphasic with a terminal half-life of 118 min."( Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Gall, H; Kraal, I; Lankelma, J; Leyva, A; Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1984
)
0.49
" In addition, uridine pharmacokinetics were associated with a time-dependent relationship as evidenced by an increased total plasma clearance, renal clearance and volume of distribution, resulting in a substantial decrease in uridine peak concentration with time."( Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.
Anderson, DC; Cretton, EM; el Kouni, MH; Kidd, LB; McClure, HM; Sommadossi, JP, 1995
)
0.29
" The absorption and pharmacokinetic parameters of 5'-DFUR and its active metabolite 5-FU, after administration of 5'-DFUR in combination with AcyT, were evaluated in the animals."( Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration.
Fukushima, S; Hamada, A; Kawaguchi, T; Morinaga, A; Nakano, M; Saneyoshi, M, 1993
)
0.29
"To evaluate the effect of the oral fluoropyrimidines, tegafur and uracil (UFT) and 5-fluorouracil (5-FU), a pharmacodynamic analysis was conducted using a nude mouse system and patients."( A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer.
Hishinuma, S; Ikeda, T; Inada, T; Kotake, K; Koyama, Y; Kubota, T; Ogata, Y; Ozawa, I; Shimizu, H, 1993
)
0.52
" Pharmacokinetic parameters [ftorafur, uracil, 5-fluorouracil (5-FU), 5-methyltetrahydrofolate] showed wide interpatient variations."( A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer.
Creaven, PJ; Frank, C; Ho, DH; Kurowski, M; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1996
)
0.82
" It was expected that AcyT would only inhibit the phosphorolytic degradation of 5'-DFUR to 5-FU, but the effect was more evident on the pharmacokinetic parameters of 5-FU than on those of 5'-DFUR."( Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.
Fukushima, S; Hamada, A; Kawaguchi, T; Nakano, M; Saneyoshi, M; Shimizu, S, 1996
)
0.52
" Pharmacokinetic examination after intravenous injection of low-dose MMC (0."( A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics.
Boku, N; Ishii, H; Kaneko, K; Kusada, O; Muro, K; Muto, M; Ohkuwa, M; Ohtsu, A; Sasaki, Y; Tajiri, H; Yoshida, S, 1996
)
0.51
"Twelve patients completed the bioavailability and pharmacokinetic studies."( Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Adjei, AA; Baker, SD; Donehower, RC; Doucette, M; Grochow, LB; Hohneker, JA; Khor, SP; Noe, DA; Rowinsky, EK; Sartorius, SE; Spector, T, 1996
)
0.53
" Estimates of 5-FU dose in combination with 776C85 were determined from pharmacokinetic and toxicodynamic analysis."( Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.
Amyx, H; Baccanari, DP; Davis, ST; Khor, SP; Nelson, D; Spector, T, 1997
)
0.54
" Pharmacokinetic evaluation showed that single-dose UFT results in maximum plasma levels and an area under the concentration-time curve that increased with escalating UFT doses."( Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Pazdur, R, 1997
)
0.3
"This study was performed to improve the prognosis of unresectable (primary non-curative and recurrent) colorectal carcinoma by using pharmacokinetic modulating chemotherapy (PMC), a combination of oral UFT and continuous venous 5FU infusion."( The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas.
Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H,
)
0.13
" Pharmacokinetic and pharmacodynamic studies were conducted to look for a relationship between the ratio of UH(2) to U and 5-FU metabolic outcome and tolerance."( Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999
)
0.63
"We performed pharmacokinetic modulating chemotherapy (PMC) postoperatively in patients with advanced gastric cancer and examined its antitumor and the side effects."( [PMC (pharmacokinetic modulating chemotherapy) for advanced gastric cancer].
Fujiwara, Y; Itoh, R; Kusunoki, M; Nakagawa, K; Nakao, K; Yamamura, T, 1999
)
0.3
" The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds."( [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Hirakawa, Y; Kawaguchi, Y; Kuwata, K; Matsushima, E; Nagayama, S, 2000
)
0.31
" There was also an increase in plasma uracil and unmetabolised 18F-fluorouracil and an increase in the radiotracer half-life in tumours (2."( Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.
Aboagye, EO; Brady, F; Jones, T; Lucas, SV; Osman, S; Price, PM; Saleem, A; Suttle, B; Yap, J, 2000
)
0.9
"Two events strongly suggested increased exposure of 18F-fluorouracil and its anabolites in the tumours, consistent with the inactivation of dihydropyrimidine dehydrogenase: a selective decrease in radiotracer exposure in normal liver and kidneys compared with tumours; and an increase in radiotracer half-life in tumours."( Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.
Aboagye, EO; Brady, F; Jones, T; Lucas, SV; Osman, S; Price, PM; Saleem, A; Suttle, B; Yap, J, 2000
)
0.87
"We encountered a case of unresectable colon cancer that disappeared following pharmacokinetic modulating chemotherapy (PMC)."( [A case report of unresectable colon cancer that disappeared following pharmacokinetic modulation chemotherapy (PMC)].
Asahara, T; Nakahara, H; Nakahara, M; Okajima, M; Yano, M, 2000
)
0.31
" Intermittent hepatic arterial infusion of high-dose 5-FU was started on a weekly schedule and oral UFT was added as pharmacokinetic modulating chemotherapy 4 weeks after the initial chemotherapy."( [A successful case of preoperative intermittent hepatic arterial infusion of high-dose 5-FU and pharmacokinetic modulating chemotherapy against unresectable liver metastasis of colon cancer].
Hamazaki, K; Inagaki, M; Kawashima, T; Morichika, T; Sadamori, H; Shima, Y; Tanaka, N; Uetsuka, H; Yagi, T, 2000
)
0.31
"Patients received a single 24-hour infusion of 5-FU (2,300 mg/m(2) on day 2) with leucovorin (15 mg orally [PO] bid on days 1 through 3) to provide reference pharmacokinetic data."( Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Bi, DQ; Donavan, S; Grem, JL; Grollman, F; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Quinn, MG; Shapiro, J; Takimoto, CH; Zentko, S, 2000
)
0.55
" To determine the bioequivalence of the combined eniluracil/5-FU dosing forms compared to the separate tablets, an analysis of variance on pharmacokinetic parameters reflecting eniluracil and 5-FU exposure was performed."( Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Cohen, D; Drengler, R; Ertel, VP; Hoffman, C; Hsieh, A; Hurwitz, HI; Magnum, S; Monroe, P; Ochoa, L; Petros, WP; Rowinsky, EK; Schwartz, G; Thomas, JP; Wilding, G, 2000
)
0.79
" The correlation between pharmacokinetic parameters and toxic effects of UFT was evaluated."( Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
Brown, N; Covington, W; Creaven, PJ; Hayakawa, T; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Lin, SN; Meropol, NJ; Pazdur, R; Rustum, YM, 2000
)
0.82
" Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as a pharmacokinetic modulating chemotherapy (PMC)."( [A case of nonresectable scirrhous type gastric cancer treated by hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy].
Ishikawa, T; Kobayashi, M; Matsuki, H; Mita, Y; Tashiro, K; Tashiro, S, 2001
)
0.57
" He was treated postoperatively with arterial infusion pharmacokinetic modulating chemotherapy (PMC) and venous infusion CPT-11 (modified PMC)."( [A case of rectal cancer with multiple liver metastases that responded dramatically to pharmacokinetic modulating chemotherapy/CPT-11 therapy].
Dan, T; Kitayama, Y; Kosaka, H; Maeda, S; Matsusaka, S; Okada, T; Tanabe, H; Yamasaki, H, 2002
)
0.31
"We treated a patient with unresectable rectal cancer with multiple liver, pulmonary and lymph node metastases that responded remarkably to pharmacokinetic modulating chemotherapy (PMC)."( [A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy].
Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002
)
0.31
" Administration of modified pharmacokinetic modulating chemotherapy (PMC) using Leucovorin (intravenous infusion of 5-FU, 600 mg/m2/24 hours; oral administration of UFT, Taiho Pharmaceutical Co."( [A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin].
Hatada, T; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Ojima, E, 2002
)
0.31
" During the test period all patients received eniluracil 50 mg orally on days 1-3 and 5-FU 10 mg/m(2) together with pharmacokinetic measurements."( A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Beale, P; Ertel, P; Judson, I; O'Donnell, A; Punt, CJ; Suttle, AB; Van Maanen, L, 2003
)
0.82
" 5-FU dose modification, on the basis of the test dose pharmacokinetic data for the patients with renal function impairment, accurately resulted in drug exposure in the potentially therapeutic range."( A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Beale, P; Ertel, P; Judson, I; O'Donnell, A; Punt, CJ; Suttle, AB; Van Maanen, L, 2003
)
0.56
" The combination can also be given to patients with renal impairment using a test dose and pharmacokinetic measurements to predict the appropriate dose of 5-FU."( A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Beale, P; Ertel, P; Judson, I; O'Donnell, A; Punt, CJ; Suttle, AB; Van Maanen, L, 2003
)
0.56
"Advanced unresectable hepatocellular carcinoma (HCC) was treated with modified pharmacokinetic modulation chemotherapy (PMC)."( [Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC].
Ito, T; Kamachi, H; Kamiyama, T; Kondo, M; Kurauchi, N; Matsushita, M; Nakagawa, T; Nishikawa, M; Ogata, T; Todo, S, 2002
)
0.31
"To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV)."( Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003
)
0.8
" infusion of 5-FU 2300 mg/m(2) to provide a pharmacokinetic reference."( Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003
)
0.57
" EU on either schedule decreased 5-FU plasma clearance by 48 to 52-fold, prolonged the half-life to >5 h, and increased the percentage of 5-FU excreted in the urine from 2% to 64-66%."( Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003
)
0.57
"Either a single 20-mg dose of EU given prior to or for 3 days around the oral 5-FU dose led to comparable effects on 5-FU pharmacokinetic parameters, and inhibition of dihydropyrimidine dehydrogenase and thymidylate synthase."( Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003
)
0.57
" Dog pharmacokinetic parameters of 12 (RO700004) and its metabolite 40 (RO1104253) were established."( Synthesis, pharmacology and pharmacokinetics of 3-(4-aryl-piperazin-1-ylalkyl)-uracils as uroselective alpha1A-antagonists.
Arias, L; Blue, DR; Chan, R; Clarke, DE; Elworthy, TR; Ford, AP; Guzman, A; Jaime-Figueroa, S; Jasper, JR; Lopez, FJ; Morgans, DJ; Padilla, F; Perez-Medrano, A; Quintero, C; Romero, M; Sandoval, L; Smith, SA; Williams, TJ, 2003
)
0.55
"The pharmacokinetics of ftorafur, 5-fluorouracil (5FU) and uracil were investigated in order to built a population pharmacokinetic model for the anticancer drug UFT, administered with leucovorin and vinorelbine."( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003
)
0.86
"Of the 31 patients treated, 30 were available for the pharmacokinetic analysis."( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003
)
0.6
"A pharmacokinetic model for ftorafur and 5FU was developed and should be useful to further study drug interactions and establish dosing guidelines."( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003
)
0.6
" Pharmacokinetic modulating chemotherapy (PMC) was performed after the operation."( [A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy].
Futamura, N; Matsutomo, M; Sakamoto, K; Tateyama, K; Yasumura, M, 2003
)
0.32
" Pharmacokinetic modulating chemotherapy (PMC), a combination of infused 5-fluorouracil and oral uracil-tegafur, has been proven to be highly effective for the treatment of colorectal carcinoma."( Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil, UFT, and taxotere (docetaxel) for advanced gastric cancer.
Kobayashi, M; Konishi, N; Kusunoki, M; Mohri, Y; Ohmori, Y; Tanaka, K; Tonouchi, H, 2003
)
0.78
" He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11."( [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H, 2004
)
0.32
" This study assessed the tolerance to Ro 09-4889 treatment, and related pharmacokinetic and pharmacodynamic data such as inhibition of DPD activity in peripheral blood mononuclear cells (PBMCs) and plasma uracil levels."( Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889.
Banken, L; Bellibas, SE; Brivet, B; Bush, ED; Chamorey, E; Kircher, C; Milano, G; Nave, S; Patel, I; Renée, N, 2004
)
0.51
" Blood samples for the pharmacokinetic study were obtained after the initial dose on day 1 of the first course."( Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Abbruzzese, JL; Boku, N; Hoff, PM; Hyodo, I; Loehrer, PJ; Muro, K; Nagashima, F; O'Dwyer, PJ; Ohtsu, A; Shirao, K; Wadleigh, RG; Wadler, S; Yamada, Y, 2004
)
0.56
"The efficacy and pharmacokinetic parameters of UFT and LV are comparable in Japanese and American patients; however, a difference in toxicity profile, specifically diarrhea, was noted."( Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Abbruzzese, JL; Boku, N; Hoff, PM; Hyodo, I; Loehrer, PJ; Muro, K; Nagashima, F; O'Dwyer, PJ; Ohtsu, A; Shirao, K; Wadleigh, RG; Wadler, S; Yamada, Y, 2004
)
0.56
"The main purpose of the present review article was to shed light on the different 5-fluorouracil (5-FU) prodrugs by underlining their respective pharmacological features in terms of metabolic activation, dihydropyrimidine dehydrogenase inhibition, pharmacokinetic profile and biomodulation ability."( Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Ferrero, JM; François, E; Milano, G, 2004
)
0.54
" To determine the plasma dihydrouracil/uracil ratio (DUUR) as a potential index for setting 5-FU/FUDR doses, the authors conducted a prospective study on the relationships of the DUUR with 5-FU/FUDR pharmacokinetic and pharmacodynamic parameters."( Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.
Hu, P; Jiang, H; Jiang, J; Lu, J, 2004
)
0.9
" In this study, a pharmacokinetic model was developed, in an attempt to evaluate the bioavailability of FTD in these animals after the co-administration of TPI."( Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
Harashima, H; Kamiya, H; Kuwata, K; Nagayama, S; Tsuchiya, H; Yamashita, K, 2004
)
0.32
" We conducted an analysis to evaluate the efficacy and feasibility of modified pharmacokinetic modulating chemotherapy, for gastric cancer patients with peritoneal dissemination."( [Modified pharmacokinetic modulating chemotherapy for progressive gastric cancer accompanied by peritoneal dissemination].
Ishikawa, T; Kamimura, T; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Watanabe, K; Yoshida, T, 2005
)
0.33
" Furthermore, she was administered tegafur/uracil (400 mg/day) 5 days weekly for pharmacokinetic modulating chemotherapy (PMC)."( [A case of advanced gastric cancer with bone metastasis and severe DIC responding to hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy].
Ishikawa, T; Kamimura, T; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Watanabe, K; Yoshida, T, 2005
)
0.59
" For this reason, a sensitive HPLC method for the analysis of 5-FU and 5-fluoro-5,6-dihydrouracil (5-FDHU) was developed in the present study for the determination of DPD activity in nucleated cells of peripheral blood and pharmacokinetic analysis of 5-FU and 5-FDHU in humans."( Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.
Amadori, D; Amatori, F; Bocci, G; Ciofi, L; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Ibrahim, T; Lastella, M; Martelloni, BM; Vannozzi, F, 2005
)
0.84
" The aim of the present study was to re-evaluate the pharmacokinetics of uracil and its metabolites using a sensitive assay and based on a newly developed, physiologically based pharmacokinetic (PBPK) model."( Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.
Hirao, Y; Inada, M; Inoue, Y; Ito, S; Kawamura, T; Koga, T; Kunizaki, J; Sato, H; Shimizu, T, 2005
)
0.78
" Pharmacokinetic variables were determined using noncompartmental methods."( The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
Desmond, RA; Diasio, RB; Fourie, J; Hirao, Y; King, JR; Koga, T; Mattison, LK; Shimizu, T, 2006
)
0.89
" These pharmacokinetic data further support the future use of the UraBT as a screening test to identify DPD deficiency before 5-fluorouracil-based therapy."( The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
Desmond, RA; Diasio, RB; Fourie, J; Hirao, Y; King, JR; Koga, T; Mattison, LK; Shimizu, T, 2006
)
1.1
"The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of alpha,alpha,alpha-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione)."( Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006
)
0.33
"A physiologically based pharmacokinetic (PBPK) model to simulate the plasma concentration and 13CO2 exhalation after [2-13C]uracil administration to DPD-suppressed dogs was developed."( Pharmacokinetic modelling of [2-13C]uracil metabolism in normal and DPD-deficient dogs.
Hirao, Y; Inada, M; Itose, M; Koga, T; Kunizaki, J; Sato, H; Shimizu, T, 2006
)
0.82
"The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies."( The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E, 2007
)
0.34
" We aimed to develop a pharmacokinetic model to describe the kinetics of tegafur and 5-FU after the administration of TS-1 and UFT."( Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Hori, S; Inoue, S; Ohtani, H; Sawada, Y; Tsujimoto, M, 2007
)
0.34
"From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil."( Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p
Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007
)
0.69
" The pharmacokinetic parameters were analysed after logarithmic transformation according to a general linear model."( A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007
)
0.6
"To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)."( Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008
)
0.35
"This study was conducted to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), and tolerability profiles and explore the efficacy of multiple oral doses of alogliptin in patients with T2D."( Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Mekki, QA; Wann, ER, 2008
)
0.35
" Blood and urine were collected over 72 hours after dosing for pharmacokinetic analysis and determination of plasma DPP-4 inhibition and active glucagon-like peptide -1(GLP-1) concentrations."( Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Mekki, QA; Wann, ER, 2008
)
0.35
" A physiologically based pharmacokinetic (PBPK) model was developed and fitted to experimental data from literature."( A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration.
Dhiman, A; Shuler, ML; Sung, JH, 2009
)
0.35
"To investigate the possible use of a (13)C-uracil breath test for gastric emptying by evaluating the pharmacokinetic properties of (13)C-uracil in a breath test in rats, in comparison with (13)C-acetate and (13)C-octanoate, traditional (13)C-probes for gastric emptying."( Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats.
Hirao, Y; Inada, M; Kashimoto, M; Kunizaki, J; Sato, H; Sugiyama, E; Tobita, K; Yoshida, T, 2009
)
0.87
"This study showed that (13)C-uracil has desirable pharmacokinetic properties as an in vivo probe of gastric emptying."( Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats.
Hirao, Y; Inada, M; Kashimoto, M; Kunizaki, J; Sato, H; Sugiyama, E; Tobita, K; Yoshida, T, 2009
)
0.9
" Potential pharmacokinetic (PK) drug-drug interactions of alogliptin with pioglitazone or glyburide were evaluated in healthy adults."( Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Fleck, P; Karim, A; Laurent, A; Mekki, Q; Munsaka, M; Wann, E, 2009
)
0.35
"Intrahepatic cholangiocellular carcinoma after curative surgery was treated with pharmacokinetic modulation chemotherapy (PMC) as adjuvant chemotherapy."( [Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma].
Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakagawa, T; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2009
)
0.35
" This study investigated (1) the effect of food on alogliptin pharmacokinetics and tolerability and (2) pharmacokinetic interactions between alogliptin and metformin or cimetidine and tolerability of alogliptin when administered with either drug."( Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Li, X; Mekki, Q; Wann, E, 2010
)
0.36
" Pharmacokinetic parameters were determined after the last dose in each period."( Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Li, X; Mekki, Q; Wann, E, 2010
)
0.36
"High throughput screening (HTS) of our compound file provided an attractive lead compound with modest P2X(7) receptor antagonist potency and high selectivity against a panel of receptors and channels, but also with high human plasma protein binding and a predicted short half-life in humans."( Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.
Beaulieu, AM; Chang, SP; Dombroski, MA; Duplantier, AJ; Gabel, CA; Jordan, C; Kalgutkar, AS; Kraus, KG; Labasi, JM; Mussari, C; Perregaux, DG; Shepard, R; Subramanyam, C; Taylor, TJ; Trevena, KA; Whitney-Pickett, C; Yoon, K, 2011
)
0.6
" Potential predictive pharmacokinetic parameters and pharmacodynamic biomarkers have been found."( Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Allegrini, G; Arrighi, G; Barletta, MT; Bocci, G; Brandi, G; Canu, B; Chericoni, S; Ciarlo, A; Danesi, R; Di Desidero, T; Di Paolo, A; Falcone, A; Fioravanti, A; Fontana, A; Giusiani, M; Kerbel, RS; Loupakis, F; Lucchesi, S; Masi, G; Orlandi, P, 2012
)
0.38
" In addition, compound 50c exhibited a markedly improved pharmacokinetic profile as a result of the introduction of a benzylic hydroxy group and significantly enhanced the antitumor activity of 5-fluorouracil against human breast cancer MX-1 xenograft model in mice."( 1,2,3-Triazole-containing uracil derivatives with excellent pharmacokinetics as a novel class of potent human deoxyuridine triphosphatase inhibitors.
Chong, KT; Endoh, K; Fujioka, A; Fukuoka, M; Hashimoto, A; Itou, K; Miyahara, S; Miyakoshi, H; Muto, T; Nagasawa, H; Nomura, M; Shuto, S; Taguchi, J; Takao, Y; Ueno, H; Wakasa, T; Yamamura, K; Yano, W; Yokogawa, T, 2012
)
0.87
" The pharmacokinetic parameters of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil after single oral administration were as follows: (2,207 +/- 545), (220."( [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Chu, Y; Ding, L; Liu, HY; Yu, Y; Zhu, H, 2012
)
0.63
" 5-FU pharmacokinetic and pharmacodynamic studies were performed using DPD circadian variation in rats with 1,2-dimethylhydrazine-induced CRC."( Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer.
Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013
)
0.65
" Furthermore, by plotting the observed pharmacokinetic parameters of 5-FU against hepatic DPD activity levels predicted by the ratio of UH2/Ura in plasma, AUC0-∞ , CLtot and half-life (t1/2 ) were closely linked to predicted hepatic DPD activity levels."( A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Nishimura, A; Okada, K; Shibata, N; Takada, K, 2013
)
0.65
" Four of the five commercially available DPP-4 inhibitors are subject to significant renal clearance, and pharmacokinetic studies in people with renal impairment have led to lower recommended doses based on creatinine clearance in order to prevent drug accumulation."( Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
Davis, TM, 2014
)
0.4
"This review considers the pharmacokinetic profile, adverse effects and drug interactions of DPP-4 inhibitors."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" However, DPP-4 inhibitors have certain differences in their pharmacokinetic properties that may be associated with different clinical effects and adverse event profiles."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" The validated HPLC method was successfully applied to a pharmacokinetic study of W-1 in rats."( Development and validation of a high performance liquid chromatography method for determination of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1), a novel non-nucleoside reverse transcriptase inhibitor and its application to a pharmacokinetic study in rats
Li, P; Liu, JY; Lou, YQ; Lu, C; Lu, YY; Ren, H; Wang, X; Wang, XW; Zhang, GL, 2015
)
0.62
" No clinically relevant pharmacokinetic interactions between the two agents have been described and the fixed-dose combination has shown bioequivalence with alogliptin and pioglitazone given separately."( Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
Scheen, AJ, 2015
)
0.42
"7) h mg/l], elimination half-life [t 1/2 21 (SD 7) vs."( Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015
)
0.67
" Plasma samples were collected through 144 hours after administration for pharmacokinetic assessments."( Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ, 2015
)
0.42
"The availability of intravenous and oral pharmacokinetic data in animals enabled the allometry scaling of 6 DPP-IV inhibitors."( Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
Bhamidipati, RK; Gilibili, RR; Mullangi, R; Srinivas, NR, 2015
)
0.42
" Patients were given single doses of TAS-102 (35 mg/m(2) ) in the pharmacokinetic phase and received twice-daily doses of TAS-102 in 28-day cycles in the repeated administration phase for evaluating efficacy and safety."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43
"Total exposure, measured by area under the plasma concentration-time curve (AUC), was generated for the DAAs, ritonavir, and ribavirin using population pharmacokinetic modeling of data (N = 2093 patients) from 6 Phase 3 studies and 1 Phase 2 study."( Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
Badri, PS; Eckert, D; Menon, RM; Mensing, S; Polepally, AR, 2017
)
0.46
" The success of these dosing recommendations was evaluated by analyzing pharmacokinetic data from liver transplant recipients in the CORAL-I study."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"A population pharmacokinetic model was developed using tacrolimus dosing and Ctrough data before and during 3D treatment (n = 29)."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"A one-compartment model with first-order absorption adequately described tacrolimus pharmacokinetic profiles during the first 4 weeks of 3D treatment."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"This study aims to develop and validate a simple, rapid and sensitive ultra-performance liquid chromatography with tandem mass spectrometry (UHPLC-MS/MS) method for exploring pharmacokinetic characteristics of trelagliptin."( A rapid and sensitive UHPLC-MS/MS assay for the determination of trelagliptin in rat plasma and its application to a pharmacokinetic study.
Cai, JP; Chen, Z; Hu, GX; Hu, XX; Lan, T; Tang, PF; Yang, CC; Yuan, LJ, 2016
)
0.43
"The population pharmacokinetic models for each component of the 3D ± ribavirin regimen (DAAs and ritonavir, n = 2348) and ribavirin (n = 1841) adequately described their respective plasma concentration-time data."( Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S, 2017
)
0.46
" To determine the rate of DPP-4 inhibition induced by these inhibitors, pharmacokinetic and pharmacodynamic parameters were used to theoretically examine the relationship between the rate of DPP-4 inhibition and clinical efficacy following the administration of four different DPP-4 inhibitors (sitagliptin, vildagliptin, alogliptin, linagliptin) by focusing on the increase in the level of glucagon-like peptide-1 (GLP-1) induced by their administration."( Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
Kimura, K; Takayanagi, R; Uchida, T; Yamada, Y, 2017
)
0.46
" Dasabuvir exhibits linear pharmacokinetics with a terminal half-life of approximately 5-8 h, allowing for twice-daily dosing."( Clinical Pharmacokinetics of Dasabuvir.
Dutta, S; Khatri, A; King, JR; Menon, RM; Zha, J, 2017
)
0.46
" A physiologically based pharmacokinetic (PBPK) model was developed for dasabuvir to evaluate the DDI potential with clopidogrel, the acyl-β-D glucuronide metabolite of which has been reported as a strong mechanism-based inhibitor of CYP2C8 based on an interaction with repaglinide."( Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.
Badri, P; Bow, D; Fischer, V; Fu, W; Shebley, M, 2017
)
0.46
" This assay was successfully applied to pharmacokinetic and murine 4T1 breast tumor xenograft studies of AZD3965 in mice."( Development and validation of a liquid chromatography tandem mass spectrometry assay for AZD3965 in mouse plasma and tumor tissue: Application to pharmacokinetic and breast tumor xenograft studies.
Guan, X; Morris, ME; Ruszaj, D, 2018
)
0.48
" Intensive or sparse pharmacokinetic sampling was performed for assessments of plasma drug concentrations."( Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
Alves, K; Ding, B; Luo, Y; Menon, RM; Mobashery, N; Wang, H; Yu, C; Zha, J; Zhao, W, 2019
)
0.51
"Collectively, the results of these pharmacokinetic analyses support the use of the same dose of the 3D regimen for Asian and Western patients."( Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
Alves, K; Ding, B; Luo, Y; Menon, RM; Mobashery, N; Wang, H; Yu, C; Zha, J; Zhao, W, 2019
)
0.51
" The current study objectives were to assess the preclinical pharmacokinetics of mavacamten for the prediction of human dosing and to establish the potential need for clinical pharmacokinetic studies characterizing drug-drug interaction potential."( In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin.
Brun, P; Carlson, TJ; Dick, R; Driscoll, JP; Erve, JCL; Evanchik, M; Grillo, MP; Haste, N; Markova, S, 2019
)
0.51
" To this end, an approach using a population pharmacokinetic (PPK)/pharmacodynamic (PD) model incorporating autoinduction was planned; however, the utility of this approach in the dose justification has not been reported."( A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114.
Araki, H; Ieiri, I; Matsuoka, K; Takahashi, K; Takenaka, T; Yamashita, F; Yoshisue, K, 2022
)
0.72
"Co-intake of ATR with Acai berry resulted in slight decrease in Cmax from 41."( Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study.
Nanjappan, SK; Ravichandiran, V; Somabattini, RA, 2022
)
0.72
"There was a significant change in the AUC0-t and Cmax of ATR, ALO and EMPA after co-administration with Acai berry."( Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study.
Nanjappan, SK; Ravichandiran, V; Somabattini, RA, 2022
)
0.72
"This study aimed to build a mathematical model of physiologically based pharmacokinetic combined DPP-4 occupancy (PBPK-DO) in humans to provide some recommendations for dosing adjustment in patients with renal impairment."( Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling.
Li, B; Liu, H; Liu, Y; Ren, C; Wang, G; Wu, C; Yu, S; Zhang, J, 2022
)
0.72

Compound-Compound Interactions

UFT is an anticancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (5-FU) combined with uracil in a molar ratio of 1: 4. Administration of 3'-MeDAB in combination with UFT delayed the appearance of oval cells and the formation of hyperplastic nodules.

ExcerptReferenceRelevance
" The administration of 3'-MeDAB in combination with 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT) delayed the appearance of oval cells and the formation of hyperplastic nodules, which were observed in the liver from 3 and 5 weeks, respectively, after the onset of 3'-MeDAB feeding, and also delayed the transient increase of serum alpha-fetoprotein level, which transiently peaked at 5 weeks, and completely suppressed the transient increase of tissue thymidylate synthetase activity, but not thymidine kinase, which were induced by 3'-MeDAB at 5 weeks, and finally reduced markedly the incidence of hepatocarcinomas."( Inhibition by 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil of hepatocarcinogenesis induced by 3'-methyl-4-dimethylaminoazobenzene in rats.
Endo, Y; Hirai, H; Kasahara, N; Kato, T; Kudo, H; Kuwa, K; Sakamoto, S; Sunaga, T; Taga, H; Uchikoshi, T,
)
0.62
"A case of local recurrence of rectal cancer was successfully treated by UFT combined with two-route CDDP chemotherapy under the AT-II induced hypertension."( [A case of local recurrence of rectal cancer successfully treated by UFT combined with two-route CDDP chemotherapy under the AT-II induced hypertension].
Ishizawa, T; Iwashige, H; Maenohara, S; Mure, H; Shimazu, H; Takao, S; Yamada, K, 1991
)
0.28
" the same therapy in combination with UFT as a maintenance therapy (group B; 8 patients)."( [Clinical evaluation of MMC-mc-chemoembolization therapy and its combination with UFT in hepatocellular carcinoma].
Matsuo, SK; Ohmura, K; Ohtsuka, Y; Suzuki, M, 1987
)
0.27
"Ten patients with carcinomatous peritonitis of gastrointestinal cancer have been treated with administrations of CDDP-Ip (50-150 mg/body), in combination with systemic chemotherapy simultaneously combined with sodium thiosulfate (STS) iv in 4 patients."( [Intraperitoneal (Ip) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: clinical evaluation and pharmacokinetics].
Fukushi, A; Hirayama, M; Koda, K; Kure, T; Morita, K; Nakazawa, O; Takahashi, H; Terada, S; Terui, T; Yoshizaki, N, 1988
)
0.27
" Mice receiving the combination of tubercidin (or nebularine) plus NBMPR-P or dilazep, as well as those that survived the combination with dipyridamole, appeared healthy and were found to have normal size livers and spleens."( Treatment of schistosomiasis by purine nucleoside analogues in combination with nucleoside transport inhibitors.
Cha, S; el Kouni, MH; Messier, NJ, 1987
)
0.27
" MKC-442 was evaluated in combination with the nucleoside analogues AZT, ddI and ddC, the non-nucleoside RT inhibitor nevirapine, the HIV-1 proteinase inhibitor Ro-31-8959, and the alpha-glucosidase 1 inhibitor, MDL-28,574, using a cell viability assay."( The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS, 1995
)
0.29
"The effectiveness of 5-fluorouracil (5-FU), FT-207 and FT-207 + uracil in combination with two repetitions of 43 degrees C hyperthermia in the treatment of the Meth-A-Fibrosarcoma and Sarcoma-180 was examined in vivo in BALB/c mice."( The antitumor effect of hyperthermia combined with fluorouracil and its analogues.
Harada, S; Matsuo, M; Miyata, M; Obara, T; Oikawa, H; Ping, L; Takahashi, T; Yanagisawa, T, 1995
)
0.83
"We evaluated the usefulness of hormonal therapy combined with UFT as initial treatment in comparison with hormonal therapy alone in 92 patients with Stage D2 prostatic cancer treated at the Department of Urology, Dokkyo University School of Medicine between 1974 and 1993."( [Clinical evaluation of chemohormonal therapy as an initial treatment for stage D2 prostatic cancer--effect of UFT administration combined with hormonal therapy].
Chen, JA; Honda, M; Hosoya, Y; Imai, T; Maeda, S; Suzuki, T; Takasaki, E, 1995
)
0.29
"We examined the effect of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone, against Toxoplasma gondii."( Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii.
Arsenijevic, D; Chang, HR; Comte, R; Pechère, JC; Polak, A; Then, RL, 1994
)
0.29
"The effects of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) on mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene (DMBA) were investigated in rats."( 1-(2-Tetrahydrofuryl)-5-fluorouracil in combination with uracil suppresses mammary carcinogenesis and growth of tumors induced with 7,12-dimethylbenz[a]anthracene in rats.
Kudo, H; Maemura, M; Mitamura, T; Nakayama, T; Sakamoto, S; Sassa, S; Suzuki, S; Yoshimura, S, 1996
)
0.84
"A comparative, randomized trial was conducted to determine the efficacy of oral UFT (Tegafur and Uracil) versus 5-fluorouracil (5-FU) in combination with cyclophosphamide and doxorubicin in patients with metastatic breast cancer."( A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital.
De Guzman, LM; Fernando, GY; Guancia, AA; Romana, IB; Samson, MC; Villalon, AH, 1997
)
0.77
"When MKC-442 was combined with 3TC and ZDV, they synergistically suppressed HIV-1 replication in MT-4 cells over a wide range of doses irrespective of the endpoints for synergy calculations."( Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.
Baba, M; Nakade, K; Piras, G; Yuasa, S, 1997
)
0.3
"Our results demonstrate a potential efficacy of MKC-442 in combination with 3TC and ZDV, and the three-drug combination should be considered for treatment of AIDS patients."( Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.
Baba, M; Nakade, K; Piras, G; Yuasa, S, 1997
)
0.3
" Oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil (UFT) markedly reduced the number and accumulated area of colonic carcinomas, and TS activity in the poorly differentiated adenocarcinomas."( Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats.
Iwama, T; Kawachi, Y; Kudo, H; Murakami, S; Okayasu, I; Sagara, T; Sakamoto, S; Tsukada, K, 1997
)
0.8
" Based on those results, we conducted a pilot study to confirm the feasibility and antitumor effect of UFT in combination with cisplatin in patients with advanced non-small cell lung cancer (NSCLC)."( Pilot study of UFT combined with 5 consecutive days cisplatin in non-small cell lung cancer.
Koinumaru, S; Matsuda, T; Nakai, Y; Saitoh, J, 1997
)
0.3
"To evaluate the efficacy of chemoendocrine therapy for the initial treatment of stage D2 prostate cancer, we conducted a prospective randomized study which compared combined androgen blockade alone to that combined with UFT."( [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
Akazawa, S; Aki, M; Hashine, K; Kuwahara, M; Sumiyoshi, Y; Takenaka, A; Yamamoto, A, 1999
)
0.3
"To determine the maximum-tolerated dose (MTD), toxicities, and pharmacokinetics of oral fluorouracil (5-FU) administered twice daily in combination with oral eniluracil, an inactivator of dihydropyrimidine dehydrogenase, administered for 28 days every 35 days."( Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Baker, SD; Diasio, RB; Donehower, RC; Grochow, LB; Hohneker, JA; Khor, SP; Lucas, VS; O'Reilly, S; Rowinsky, EK; Sartorius, SE; Spector, T, 2000
)
0.78
"35 mg/m(2) twice daily was administered with oral eniluracil 10 mg daily for 14 to 28 days, followed by a 1-week rest period."( Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Baker, SD; Diasio, RB; Donehower, RC; Grochow, LB; Hohneker, JA; Khor, SP; Lucas, VS; O'Reilly, S; Rowinsky, EK; Sartorius, SE; Spector, T, 2000
)
0.81
"Pharmacokinetic modulating chemotherapy (PMC) is a new therapeutic concept in combination with continuous 5-fluorouracil (5-FU) infusion and UFT."( Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2000
)
0.74
" We describe the design of a phase II study to investigate the safety and efficacy of UFT/leucovorin combined with mitomycin-C in a larger group of previously untreated patients with metastatic colorectal cancer."( UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca.
Jakobsen, A, 2000
)
0.31
" Protracted infusional 5-FU has been associated with decreased tumor recurrence and improved survival when combined with postoperative adjuvant pelvic radiotherapy."( Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin.
Haller, DG; Minsky, BD; Rosenthal, DI; Saltz, L; Semple, D, 2000
)
0.31
"The recommended oral dosage of 5-FU (10 mg/m(2) PO bid) given with eniluracil and leucovorin is approximately 115-fold lower than the reference dosage for 24-hour infusional 5-FU."( Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Bi, DQ; Donavan, S; Grem, JL; Grollman, F; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Quinn, MG; Shapiro, J; Takimoto, CH; Zentko, S, 2000
)
0.79
"We randomized patients with locally advanced cervical cancer to receive radiotherapy combined with transcatheter arterial infusion (TAI) of cisplatin or oral fluoropyrimidine anticancer agents, and compared the prognosis by a prospective follow-up study."( Radiotherapy combined with transcatheter arterial infusion of cisplatin versus oral fluoropyrimidine anticancer agent for locally advanced carcinoma of the uterine cervix: a prospective follow-up study.
Hirokawa, Y; Murakami, J; Nagai, N; Ohama, K; Oshita, T; Shigemasa, K,
)
0.13
"This prospective and randomized clinical study was initiated to compare the efficacy and safety of combined androgen blockade with combination with UFT in patients with untreated prostate cancer."( Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer.
Kuriyama, M; Ohshima, S; Ono, Y; Sahashi, M; Shimizu, H; Takahashi, Y; Tanaka, T, 2001
)
0.31
") UFT (250 mg/m(2)/day) for 21 days of a 28-day cycle combined with increasing intravenous (i."( Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
Alonso, V; Antón, A; Escudero, P; Herrero, A; Isla, MD; Martinez-Trufero, J; Mayordomo, JI; Sáenz, A; Tres, A; Zorrilla, M, 2001
)
0.31
"To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice."( [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002
)
0.31
" cis-Diaminedichloroplatinum (cisplatin) has been reported to immunomodulate, especially when used in low dose in combination with 5-Fluorouracil (5-FU)."( Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer.
Ando, K; Fukuzawa, M; Kanou, H; Kimura, T; Nagata, Y; Nezu, T; Shibata, M; Takekawa, M, 2002
)
0.52
"When eniluracil is given with 5-FU/LV, DPD inhibition appears to be influenced by schedule, and the time to recovery is much longer than has been observed with eniluracil given alone."( Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Grem, JL; Guo, XD; Harold, N; Keith, B; Quinn, M; Schuler, B; Shapiro, J; Zentko, S, 2002
)
0.99
"The authors conducted a single-institution Phase I clinical trial to determine the maximum tolerated doses and to define the toxic effects of oral eniluracil and oral 5-fluorouracil (5-FU) combined with docetaxel in patients with metastatic breast carcinoma."( Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Booser, DJ; Cristofanilli, M; Frye, DK; Hortobagyi, GN; Rivera, E; Rosales, MM; Valero, V, 2002
)
0.83
"The aim of this study was to evaluate the efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma (T3-T4) when delivered in combination with chemotherapy (oral tegafur-uracil modulated with leucovorin)."( Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study.
Batlle, JF; Carpeño, Jde C; García, AG; Grande, AG; Juberías, AM; Olivar, LM; Piñeiro, EH; Sánchez Santos, ME; Uzcudun, AE; Velasco, JC, 2002
)
0.72
"Our neoadjuvant radiation therapy protocol is efficient for the preoperative treatment of resectable rectal adenocarcinoma when combined with chemotherapy (oral tegafur-uracil modulated with leucovorin)."( Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study.
Batlle, JF; Carpeño, Jde C; García, AG; Grande, AG; Juberías, AM; Olivar, LM; Piñeiro, EH; Sánchez Santos, ME; Uzcudun, AE; Velasco, JC, 2002
)
0.72
" Since clinical studies have demonstrated that bisphosphonates (BPs), specific inhibitors of osteoclastic bone resorption, are beneficial for breast cancer patients with bone metastases, we next examined the effects of UFT combined with the BP zoledronic acid (ZOL) on established bone metastases."( Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Hata, K; Hiraga, T; Ikeda, F; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T, 2003
)
0.32
" In this study, the anti-HIV-1 activity of EMV in combination with two nucleoside reverse transcriptase inhibitors was examined in cell cultures."( Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Baba, M; Nitanda, T; Somekawa, K; Wang, X; Yuasa, S, 2001
)
0.31
" Therefore, we conducted a phase II study of gemcitabine combined with UFT in metastatic pancreatic cancer patients and assessed the efficacy and the toxicity of the regimen."( Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, JK; Lee, KT; Lee, MH; Lee, SI; Lim, DH; Park, JO; Park, K; Song, SY, 2004
)
0.58
"Our aim was to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended dose of oxaliplatin combined with oral tegafur-uracil and leucovorin."( Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer.
Chen, JS; Huang, JS; Liau, CT; Lin, YC; Rau, KM; Wang, HM; Yang, TS, 2005
)
0.76
") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers."( Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005
)
0.81
" The purpose of this study was to examine whether Skp2 expression can be a useful prognostic factor in oral SCC patients treated by UFT in combination with radiation."( High expression of S-phase kinase-associated protein 2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation.
Harada, K; Itashiki, Y; Kawaguchi, S; Kawashima, Y; Sato, M; Yoshida, H,
)
0.13
" Between February 2002 and October 2002, 64 patients received UFT 300 mg m(-2) day(-1) and LV 90 mg day(-1) from day 1 to day 14 combined with oxaliplatin 130 mg m(-2) on day 1, every 3 weeks."( 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
Bennouna, J; Bordenave, S; Cvitkovic, F; Dorval, E; Douillard, JY; Hebbar, M; Jacob, JH; Malek, K; Paillot, B; Perrier, H; Priou, F; Seitz, JF; Tonelli, D, 2006
)
0.63
"A total of 208 cycles of chemotherapy were given with a median of 4 per patient."( Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.
Barón, MG; Casado, E; Castañón, C; Castro, J; Cruz, M; Feliu, J; Fonseca, E; Jara, C; Jaráiz, AR; León, A; Lomas, M; Sáenz, JG, 2006
)
0.33
" We addressed the safety of oral eniluracil/5-FU combined with radiation therapy and determined the profile of dose-limiting toxicities and recommended Phase II dose (RPTD) in patients with pancreatic and hepatobiliary cancers."( A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
Cohen, DP; Czito, BG; Fernando, N; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Morse, MA; Pappas, TN; Petros, WP; Tyler, DS; Yu, D, 2006
)
0.92
" In total, 79 courses were administered with a median of 3 (range 1-6)."( UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.
Abad, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gallego, J; Gómez, A; López, E; Manzano, JL; Sastre, J, 2006
)
0.33
" The purpose of this study was to examine whether Jab1 expression can be a useful prognostic factor in OSCC patients treated by 1 M Tegafur and 4 M uracil (UFT) in combination with radiation."( High expression of Jun activation domain-binding protein 1 (Jab1) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation.
Harada, K; Kawashima, Y; Sato, M; Yoshida, H,
)
0.33
"This randomised phase II study evaluates the safety and efficacy profile of uracil/tegafur/leucovorin combined with irinotecan (TEGAFIRI) or with oxaliplatin (TEGAFOX)."( Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
Aitini, E; Bajetta, E; Barone, C; Buzzoni, R; Di Bartolomeo, M; Ferrario, E; Iop, A; Isa, L; Jacobelli, S; Lo Vullo, S; Mariani, L; Pinotti, G; Recaldin, E; Zilembo, N, 2007
)
2.01
"To evaluate the efficacy and safety of irinotecan combined with UFT for untreated and pretreated metastatic colorectal cancer."( Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer.
Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Yasuda, S, 2008
)
0.35
"A 24-hour infusion of irinotecan combined with UFT is feasible and active for metastatic colorectal cancer."( Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer.
Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Yasuda, S, 2008
)
0.35
"To test the efficacy and safety of pharmacokinetic modulating chemotherapy combined with cisplatin (PMC-cisplatin) as induction chemotherapy (ICT) before definitive treatment in patients with respectable locally advanced head and neck squamous cell carcinoma (HNSCC)."( Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Wang, LW; Wang, YF; Yang, MH, 2008
)
0.35
" These results provide a strong argument for using alogliptin in combination with pioglitazone."( The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
Asakawa, T; Kataoka, O; Moritoh, Y; Odaka, H; Takeuchi, K, 2009
)
0.35
" In this work, an artificial receptor in the format of molecularly imprinted polymer (MIP) brush 'grafted to' the surface of sol-gel immobilized on cost-effective homemade solid-phase microextraction (SPME) fibers, individually imprinted with either of Ura and 5FU, was used in combination with a voltammetric sensor duly modified with the same MIP."( Ultratrace analysis of uracil and 5-fluorouracil by molecularly imprinted polymer brushes grafted to silylated solid-phase microextraction fiber in combination with complementary molecularly imprinted polymer-based sensor.
Patel, AK; Prasad, BB; Sharma, PS; Singh, M; Srivastava, S; Tiwari, K, 2009
)
0.66
"To investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of UFT and UZEL for metastatic colorectal carcinoma (mCRC), fourteen patients were enrolled in the present study."( Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
Hattori, T; Itoh, K; Komatsu, N; Mine, T; Okuno, K; Shiozaki, H; Yamada, A, 2009
)
0.35
" Potential pharmacokinetic (PK) drug-drug interactions of alogliptin with pioglitazone or glyburide were evaluated in healthy adults."( Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Fleck, P; Karim, A; Laurent, A; Mekki, Q; Munsaka, M; Wann, E, 2009
)
0.35
" Tegafur and Uracil (UFT) have been widely used for the postoperative chemotherapy of breast cancer, and often combined with hormonal agents."( [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Noguchi, S; Taguchi, T, 2009
)
0.98
" This study investigated (1) the effect of food on alogliptin pharmacokinetics and tolerability and (2) pharmacokinetic interactions between alogliptin and metformin or cimetidine and tolerability of alogliptin when administered with either drug."( Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Li, X; Mekki, Q; Wann, E, 2010
)
0.36
"Patients with type 2 diabetes mellitus (T2DM) are generally treated with many pharmacological compounds and are exposed to a high risk of drug-drug interactions."( Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen, AJ, 2010
)
0.36
" His diagnosis was rectal perforation combined with intraperitoneal abscess."( [A case of rectal cancer combined with intraperitoneal abscess responding completely to uracil/tegafur (UFT) plus oral leucovorin (LV) therapy].
Hamaya, M; Hojyo, K; Honda, A; Kaneko, H; Kawashima, H; Narabashi, K; Noda, S; Okamoto, N; Onoda, K; Yamada, K; Yokote, K, 2010
)
0.58
"Although there are many randomized clinical trials of late course accelerated hyperfractionated radiotherapy (LCAHFR) combined with FP chemotherapy for esophageal cancer, the efficacy and toxicity are controversial."( Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Gao, XS; Li, XY; Liu, CX, 2010
)
0.36
"Reports of randomized clinical trials on LCAHFR combined with FP chemotherapy for esophageal cancer published between January 1999 and January 2009 were researched through Wanfang, CNKI, and PubMed databases."( Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Gao, XS; Li, XY; Liu, CX, 2010
)
0.36
" Of the 2030 patients, 1006 underwent LCAHFR (LCAHFR group), and 1024 underwent LCAHFR combined with FP chemotherapy (combination group)."( Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Gao, XS; Li, XY; Liu, CX, 2010
)
0.36
"LCAHFR combined with FP chemotherapy can improve the survival rate and the local control rate of the patients with esophageal cancer."( Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Gao, XS; Li, XY; Liu, CX, 2010
)
0.36
"To investigate the efficacy and toxicity of a short intensive Uracil/Tegafur (UFT) based chemoradiotherapy scheme combined with celecoxib in locally advanced pancreatic cancer."( Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.
Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011
)
0.94
"5 Gy radiotherapy combined with UFT 300 mg/m(2) per day, leucovorin (folinic acid) 30 mg and celecoxib 80 0mg for 28 days concomitant with radiotherapy."( Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.
Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011
)
0.7
"Based on the lack of response, the substantial toxicity of mainly gastro-intestinal origin and the reported mediocre overall and progression free survival, we cannot advise our short intensive chemoradiotherapy schedule combined with celecoxib as the standard treatment."( Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.
Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011
)
0.7
"To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients."( Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
Alkis, N; Benekli, M; Demirci, U; Gumus, M; Isikdogan, A; Kaplan, MA; Koca, D; Ozdemir, NY; Sevinc, A; Uncu, D; Unek, T; Yetisyigit, T; Yilmaz, U,
)
0.13
"MMC in combination with fluoropyrimidines is safe and active in heavily-pretreated MCRC patients."( Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
Alkis, N; Benekli, M; Demirci, U; Gumus, M; Isikdogan, A; Kaplan, MA; Koca, D; Ozdemir, NY; Sevinc, A; Uncu, D; Unek, T; Yetisyigit, T; Yilmaz, U,
)
0.13
"The aim of the study was to assess the efficacy and tolerability of alogliptin combined with pioglitazone in metformin-treated type 2 diabetic patients."( Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
Burant, CF; DeFronzo, RA; Fleck, P; Mekki, Q; Pratley, RE; Wilson, C, 2012
)
0.38
"5 or 25 mg qd) alone or combined with pioglitazone (15, 30, or 45 mg qd) in 1554 patients on stable-dose metformin monotherapy (≥1500 mg) with inadequate glycemic control."( Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
Burant, CF; DeFronzo, RA; Fleck, P; Mekki, Q; Pratley, RE; Wilson, C, 2012
)
0.38
" Thirteen studies were conducted to characterize drug-drug interactions for the 3D regimen of OBV, PTV/r, and DSV and various medications in healthy volunteers to inform dosing recommendations in HCV-infected patients."( Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Awni, WM; Badri, PS; Coakley, EP; Dutta, S; Hu, B; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Wang, T; Zha, J, 2015
)
0.42
"Mechanism-based drug-drug interactions were evaluated for gemfibrozil, ketoconazole, carbamazepine, warfarin, omeprazole, digoxin, pravastatin, and rosuvastatin."( Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Awni, WM; Badri, PS; Coakley, EP; Dutta, S; Hu, B; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Wang, T; Zha, J, 2015
)
0.42
" This phase 1, drug-drug interaction, open-label, multiple-dose study enrolled 32 healthy subjects to receive the 3D or 2D regimen in combination with sofosbuvir."( Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
Awni, WM; Cohen, D; Ding, B; Dutta, S; King, JR; Menon, RM; Podsadecki, TJ, 2016
)
0.43
" However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination with the 3D regimen."( Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H, 2016
)
0.43
" In the present study, the efficacy and safety of a modified (1-week shorter administration period) UFT/LV schedule combined with bevacizumab for a similar population are reported."( Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU
Amagai, K; Denda, T; Higashijima, J; Hiroshima, Y; Hyodo, I; Indo, S; Ishida, H; Maeba, T; Masuishi, T; Mizuta, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Ozeki, M; Sakai, Y; Sato, M; Shimada, M; Takahashi, I; Yamamoto, Y, 2016
)
1.88
"UFT/LV (3 weeks of therapy and 1 week without) combined with biweekly bevacizumab is a tolerable and effective treatment option for elderly patients (aged ≥ 75 years) with metastatic colorectal cancer."( Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLU
Amagai, K; Denda, T; Higashijima, J; Hiroshima, Y; Hyodo, I; Indo, S; Ishida, H; Maeba, T; Masuishi, T; Mizuta, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Ozeki, M; Sakai, Y; Sato, M; Shimada, M; Takahashi, I; Yamamoto, Y, 2016
)
1.88
" Drug-drug interaction (DDI) studies of the 3D regimen and commonly used medications were conducted in healthy volunteers to provide information on coadministering these medications with or without dose adjustments."( Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
Chiu, YL; Ding, B; Dumas, EO; Khatri, A; King, JR; Menon, RM; Podsadecki, TJ; Polepally, AR; Shuster, DL, 2016
)
0.43
"A total of 680 patients received the following antidiabetic therapies: trelagliptin monotherapy (n = 248), combination with a sulfonylurea (n = 158), a glinide (n = 67), an α-glucosidase inhibitor (n = 65), a biguanide (n = 70), or a thiazolidinedione (n = 72)."( Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study.
Inagaki, N; Kaku, K; Kuroda, S; Sano, H; Seki, Y, 2016
)
0.43
" Drug-drug interactions between 2D (ombitasvir/paritaprevir/ritonavir) or 3D (ombitasvir/paritaprevir/ritonavir and dasabuvir) regimens and omeprazole, a CYP2C19 substrate and acid-reducing agent, were evaluated in 24 healthy volunteers."( Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.
Awni, WM; Dutta, S; Hu, B; Menon, RM; Podsadecki, TJ; Polepally, AR, 2016
)
0.43
" These data indicate that the 3-direct-acting-antiviral regimen can be administered with dolutegravir or abacavir plus lamivudine without dose adjustment."( Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Zhao, W, 2016
)
0.43
" Safe and efficacious antiviral regimens resulting in minimal to no drug-drug interactions (DDIs) with antiretrovirals are needed to ensure that patients coinfected with HCV and the human immunodeficiency virus (HIV) achieve 12-week sustained virologic response rates similar to HCV-monoinfected patients."( Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
King, JR; Menon, RM, 2017
)
0.46
" The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR."( Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Goricar, K; Janez, A; Jensterle, M, 2017
)
0.46
"ALO alone and in combination with PIO improved IR along with dynamic IS and meal related β-cell function when added to MET treated PCOS."( Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Goricar, K; Janez, A; Jensterle, M, 2017
)
0.46
"Dasabuvir, a nonnucleoside NS5B polymerase inhibitor, is a sensitive substrate of cytochrome P450 (CYP) 2C8 with a potential for drug-drug interaction (DDI) with clopidogrel."( Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.
Badri, P; Bow, D; Fischer, V; Fu, W; Shebley, M, 2017
)
0.46
" This commentary outlines the US Food and Drug Administration (FDA) interdisciplinary review team's scientific perspective to address the potential for a significant drug-drug interaction (DDI) between clopidogrel and VIEKIRA PAK."( Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug-Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective.
Arya, V; Mishra, P; Reynolds, KS; Younis, IR; Zhao, P, 2017
)
0.46
"To assess drug-drug interaction (DDI) potential for the three direct-acting antiviral (3D) regimen of ombitasvir, dasabuvir, and paritaprevir, in vitro studies profiled drug-metabolizing enzyme and transporter interactions."( Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Bow, DAJ; de Morais, SM; Fischer, V; Kavetskaia, O; Liu, J; Nijsen, MJMA; Shebley, M; Sydor, J, 2017
)
0.46
"No drug-drug interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA)."( Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.
Bellissant, E; Ben Ali, Z; Boglione-Kerrien, C; Guyader, D; Jezequel, C; Lemaitre, F; Tron, C; Verdier, MC, 2017
)
0.46
" Here, we developed a uracil removal-inhibited ligase reaction in combination with catalytic hairpin assembly (CHA) for the sensitive and specific detection of UDG activity."( Uracil removal-inhibited ligase reaction in combination with catalytic hairpin assembly for the sensitive and specific detection of uracil-DNA glycosylase activity.
Jiang, W; Wang, L; Wu, Y; Xu, X, 2017
)
2.21
" Treatment in the post-transplantation setting may be complicated by significant drug-drug interactions between antiviral agents and standard immune suppressive treatment regimens."( Ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C.
Dolman, GE; Gelson, WT; Selby, P, 2018
)
0.48
"Treatment with Bmab in combination with TAS-102 is significantly associated with improved clinical outcomes in patients with mCRC refractory to standard therapies."( Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Fujii, H; Hirose, C; Iihara, H; Ishihara, T; Kitahora, M; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K, 2020
)
0.56
" Treatment with Bmab in combination with TAS-102 is significantly associated with improved clinical outcomes in patients with mCRC."( Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Fujii, H; Hirose, C; Iihara, H; Ishihara, T; Kitahora, M; Matsuhashi, N; Suzuki, A; Takahashi, T; Watanabe, D; Yamada, Y; Yoshida, K, 2020
)
0.56
"TAS-102 is a preconstituted drug combination comprising an oral fluoropyrimidine (trifluridine, TFT) and a potent inhibitor of thymidine phosphorylase (tipiracil hydrochloride, TPI)."( TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination.
Aprile, G; Cianchi, F; Fancelli, S; Gatta Michelet, MR; Lavacchi, D; Mini, E; Nobili, S; Roviello, F; Roviello, G, 2020
)
0.56
"The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies."( Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani, J, 2022
)
0.72
"Trifluridine/tipiracil could be consider a cost-effective treatment also in first-line for mCRC patients who were not candidates for combination with cytotoxic chemotherapies."( Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Giuliani, J, 2022
)
0.72
"Although the combination with PrOD significantly affects the pharmacokinetics of CsA, it is effective and safe with regular monitoring of the CsA blood concentrations and appropriate CsA dose adjustment."( Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022
)
0.72
"To explore the effects of systematic diet education combined with multidisciplinary nursing on nutritional status and calcium and phosphorus metabolism in patients with diabetic kidney disease (DKD) in uremic phase after treatment with alogliptin."( Effects of Systematic Diet Education Combined with Multidisciplinary Nursing on Nutritional Status and Calcium and Phosphorus Metabolism in Patients with Diabetic Kidney Disease in Uremic Phase after Treatment with Alogliptin.
Guo, N; Li, N; Liu, K; Sun, H; Zhao, Y, 2022
)
0.72
" The combination group received systematic dietary education combined with multidisciplinary nursing after the medication, and the conventional group received conventional intervention."( Effects of Systematic Diet Education Combined with Multidisciplinary Nursing on Nutritional Status and Calcium and Phosphorus Metabolism in Patients with Diabetic Kidney Disease in Uremic Phase after Treatment with Alogliptin.
Guo, N; Li, N; Liu, K; Sun, H; Zhao, Y, 2022
)
0.72
"With conspicuous intervention effect, systematic diet education combined with multidisciplinary nursing is a reliable method that can improve the nutritional status and levels of calcium and phosphorus metabolism, enhance treatment compliance, and reduce anxiety."( Effects of Systematic Diet Education Combined with Multidisciplinary Nursing on Nutritional Status and Calcium and Phosphorus Metabolism in Patients with Diabetic Kidney Disease in Uremic Phase after Treatment with Alogliptin.
Guo, N; Li, N; Liu, K; Sun, H; Zhao, Y, 2022
)
0.72
" First three groups were treated with Acai berry (PO; 250 mg/kg); fourth, fifth and sixth groups received sodium CMC (vehicle) for 10 days and on eleventh day, first and fourth groups were administered with ATR (PO; 10 mg/kg); second and fifth groups with ALO (PO; 25 mg/kg) and third and sixth groups received EMPA (PO; 25 mg/kg)."( Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study.
Nanjappan, SK; Ravichandiran, V; Somabattini, RA, 2022
)
0.72
"From October 2020 to February 2022, patients with metastatic colorectal cancer who failed from 2 or more lines of prior therapy and treated with TAS-102 monotherapy, in combination with bevacizumab or immune checkpoint inhibitors (ICIs) were analyzed."( An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J, 2023
)
0.91

Bioavailability

The oral administration of 5-fluorouracil (5-FU) is hindered by erratic bioavailability due to catabolism of the enzyme dihydropyrimidine dehydrogenase (DPD) in the gastrointestinal tract. Pretreatment with eniluracil sig can change the route of elimination from hepatic metabolism to renal excretion.

ExcerptReferenceRelevance
" An average absorption rate constant of 122 +/- 34 micrograms/cm2-hr was obtained from the XRF measurements on four rats."( Noninvasive in vivo percutaneous absorption measurements using X-ray fluorescence.
Ferguson, E; Jay, M; Robertson, JD; Stalker, DJ, 1992
)
0.28
" High amounts of uracil formed from uridine can interfere with the hepatic catabolism of 5-fluorouracil and thus increase its bioavailability and toxicity."( Uridine catabolism by the isolated perfused rat liver.
Gengenbacher, HM; Gerok, W; Holstege, A; Jehle, L, 1992
)
0.62
" A-73209 was orally bioavailable in mice, with maximal serum concentrations well in excess of in vitro inhibitory concentrations."( Efficacy of A-73209, a potent orally active agent against VZV and HSV infections.
Alder, J; Clement, J; Kern, ER; Marsh, K; Mitten, M; Norbeck, D, 1994
)
0.29
" 5-FU oral bioavailability was approximately 100% in rats pretreated with 5-EU."( 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.
Baccanari, DP; Davis, ST; Knick, VC; Spector, T, 1993
)
0.7
" with BAU at 90 mg/kg, and a comparison of the AUC values showed an oral bioavailability of 70%."( Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine.
Baccanari, DP; Chandrasurin, P; Davis, ST; Joyner, SS, 1993
)
0.29
" AcyT increased the maximal plasma concentration (Cmax) and apparent absorption rate constant (ka) of 5'-DFUR, as expected, but the increase in AUC (area under the curve) was not significant."( Modulation of the pharmacokinetics of 5'-deoxy-5-fluorouridine and 5-fluorouracil in rats by oral co-administration of acyclothymidine.
Fukushima, S; Hamada, A; Kawaguchi, T; Nakano, M; Saneyoshi, M; Shimizu, S, 1996
)
0.52
"To study the absolute bioavailability and pharmacokinetics of an oral solution of fluorouracil (5-FU) in patients treated with 776C85, an oral inactivator of dihydropyrimidine dehydrogenase (DPD), and to evaluate the feasibility of administering oral 5-FU and 776C85 on a multiple-daily dosing schedule."( Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Adjei, AA; Baker, SD; Donehower, RC; Doucette, M; Grochow, LB; Hohneker, JA; Khor, SP; Noe, DA; Rowinsky, EK; Sartorius, SE; Spector, T, 1996
)
0.75
"Twelve patients completed the bioavailability and pharmacokinetic studies."( Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Adjei, AA; Baker, SD; Donehower, RC; Doucette, M; Grochow, LB; Hohneker, JA; Khor, SP; Noe, DA; Rowinsky, EK; Sartorius, SE; Spector, T, 1996
)
0.53
" Trials of new combinations are warranted to take advantage of the pharmacokinetic properties and oral bioavailability of UFT and leucovorin."( Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast.
Belón, J; Blanco, E; Espinosa, E; Feliu, J; Garcia Alfonso, P; Garcia Girón, C; Garrido, P; González Barón, M; Jara, C; Ruiz, A; Vincent, JM; Zamora, P, 1997
)
0.3
" In addition, we sought to determine whether coadministration of UFT and leucovorin alters the bioavailability of these agents."( Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Birkhofer, MJ; Meropol, NJ; Noel, D; Sonnichsen, DS, 1997
)
0.3
" Initial clinical data on 5-FU combined with GW776C85 suggest potentially increased antitumor activity in at least some malignancies with tolerable toxicity, as well as several distinct economic and quality-of-life advantages including the following: (1) The possibility of administering 5-FU as an oral drug due to excellent bioavailability of 5-FU following inactivation of DPD; (2) a cost-effective alternative to continuous or protracted infusion of 5-FU without the need for hospitalization or surgical placement of an intravenous access and availability of an ambulatory pump; and (3) potential for less interpatient variation of 5-FU toxicity (e."( Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator.
Diasio, RB, 1998
)
0.3
"6 h in dogs, with bioavailability levels of 85% (30 mg/kg) and 42."( Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
Burtness, BA; Calabresi, P; Chu, E; Chu, MY; Chu, SH; Darnowski, JW; Handschumacher, RE; Leffert, JJ; Marsh, JC; Pizzorno, G; Yee, L, 1998
)
0.3
" Early clinical studies have shown a substantial alteration of the systemic disposition of 5-FU with an increase in 5-FU terminal half-life and have also indicated that EU allows safe oral administration of 5-FU by improving the oral bioavailability of the fluoropyrimidine, which is otherwise too erratic and unpredictable for a drug with such a limited therapeutic window."( In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
Adams, ER; Craig, DJ; Leffert, JJ; Pizzorno, G; Spector, T, 1999
)
0.6
" In addition, a three-treatment by three-period crossover bioavailability comparison of oral LV 30 mg plus UFT 200 mg versus either LV or UFT alone was scheduled for the 8 days preceding the first cycle of therapy."( Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Birkhofer, MJ; Ferreira, I; Meropol, NJ; Noel, D; Sonnichsen, DS, 1999
)
0.3
" However, the great interpatient variability observed in UFT and LV pharmacology may have obscured true bioavailability effects in this small patient population."( Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Birkhofer, MJ; Ferreira, I; Meropol, NJ; Noel, D; Sonnichsen, DS, 1999
)
0.3
" However, marked intra- and interpatient variability, combined with nonlinear elimination kinetics and erratic oral bioavailability are relative limitations to further development of 5-FU."( The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Papamichael, D, 1999
)
0.3
" It showed good oral bioavailability in rats (68."( Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.
Aoki, M; Iwayama, S; Mukai, C; Nakagawa, R; Nakazawa, H; Ohmura, Y; Okunishi, M; Onishi, T; Ono, N; Sekiyama, T; Suzuki, K; Tsuji, T, 2000
)
0.54
"The purpose of this investigation was to evaluate the efficacy of oral 5-(phenylselenenyl)-acyclouridine (PSAU) in increasing endogenous plasma uridine concentration as well as its ability to improve the bioavailability of oral uridine."( Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy.
Al Safarjalani, ON; Ashour, OM; el Kouni, MH; Goudgaon, NM; Naguib, FN; Schinazi, RF, 2000
)
0.31
"PSAU has an oral bioavailability of 100% and no PSAU metabolites were detected."( Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy.
Al Safarjalani, ON; Ashour, OM; el Kouni, MH; Goudgaon, NM; Naguib, FN; Schinazi, RF, 2000
)
0.31
" The potential benefit of long bioavailability and oral delivery of UFT compares favorably with continuous infusion regimens without the added morbidity of a catheter and pump."( A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
Bonner, JA; Childs, HA; Newsome, J; Raben, D; Robert, F; Spencer, SA, 2000
)
0.31
" Numerous active 5-FU schedules are in clinical use, but erratic oral bioavailability has historically mandated intravenous administration."( Oral therapy for colorectal cancer: how to choose.
Damjanov, N; Meropol, NJ, 2000
)
0.31
" PSAU has 100% oral bioavailability and is a powerful enhancer of the bioavailability of oral uridine."( Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2',3',5'-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy.
Ashour, OM; el Kouni, MH; Goudgaon, NM; Naguib, FN; Schinazi, RF, 2000
)
0.31
" However, oral administration of 5-FU has been hampered by incomplete and erratic bioavailability due to substantial variability in the activity of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-FU catabolism."( Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Kindler, HL; Schilsky, RL, 2000
)
0.87
" In the presence of eniluracil, bioavailability of 5-FU has increased to approximately 100%, the half-life is prolonged to 4 to 6 hours, and systemic clearance is reduced > 20-fold to values comparable the glomerular filtration rate (46 to 58 mL/min/m2)."( Pharmacology of fluorinated pyrimidines: eniluracil.
Baker, SD, 2000
)
0.87
"The oral administration of 5-fluorouracil (5-FU) is hindered by erratic bioavailability due to catabolism of 5-FU by the enzyme dihydropyrimidine dehydrogenase (DPD) in the gastrointestinal tract."( Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001
)
0.88
" The unpredictable and low oral bioavailability of 5FU initially discouraged this form of treatment."( The oral fluorinated pyrimidines.
de Bono, JS; Twelves, CJ, 2001
)
0.31
" The effect of food on the oral bioavailability of UFT (2 x 100 mg capsules; dose in terms of FT) and leucovorin (2 x 15 mg tablets) was evaluated in a single-dose, randomized, two-way crossover study."( Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001
)
0.31
" The supply of folate depends primarily on the quantity and bioavailability of ingested folate and the rate of loss by urinary and fecal routes and through catabolism."( Prevention of pathologies associated with oxidative stress and dietary intake deficiencies: folate deficiency and requirements.
Gaté, L; Machover, D; Tapiero, H; Tew, KD, 2001
)
0.31
" Administration of 5-FU and eniluracil with food resulted in a decrease in the 5-FU absorption rate constant by 90%."( Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
Ertel, P; Fleming, GF; Janisch, L; Kastrissios, H; Learned-Coughlin, S; Magnum, S; Mani, S; Ratain, MJ; Schilsky, RL; Shepard, DR; Smith, D, 2002
)
0.83
" Pretreatment with eniluracil significantly increases plasma half-life, plasma concentration and oral bioavailability of 5-FU."( Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002
)
0.93
" Further research is needed to clarify the role of choline and methionine concentration and the importance of the reduced folate carrier and the folate receptor in determining the relative bioavailability of 5-MeTHF and FA with regard to genome stability."( A comparison of folic acid and 5-methyltetrahydrofolate for prevention of DNA damage and cell death in human lymphocytes in vitro.
Fenech, M; Wang, X, 2003
)
0.32
" Concurrent administration of oral eniluracil with oral 5-FU not only increases the bioavailability of 5-FU, owing to elimination of first-pass metabolism, but can change the route of elimination of 5-FU from hepatic metabolism to renal excretion."( A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Beale, P; Ertel, P; Judson, I; O'Donnell, A; Punt, CJ; Suttle, AB; Van Maanen, L, 2003
)
0.83
"Eniluracil increases the oral bioavailability of 5-FU and results in a switch from hepatic metabolism to renal elimination."( A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Beale, P; Ertel, P; Judson, I; O'Donnell, A; Punt, CJ; Suttle, AB; Van Maanen, L, 2003
)
1.12
" Inactivation of DPD using eniluracil is advantageous in that it renders 5-FU orally bioavailable with more predictable pharmacokinetics and blocks one of the major potential mechanisms of 5-FU chemoresistance."( Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
Diasio, RB; Heslin, MJ; Lucas, VS; Owens, J; Shao, L; Weiss, H; Yan, J, 2003
)
0.83
" Compound 42 was reasonably well absorbed in mice after oral administration."( Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: discovery of novel orally active inhibitors of human thymidine phosphorylase.
Asao, T; Emura, T; Fukushima, M; Kazuno, H; Suzuki, N; Tada, Y; Wierzba, K; Yamada, Y; Yamashita, J; Yano, S, 2004
)
0.58
" Selected compounds from this series featured good oral bioavailability in mice and cynomolgus monkeys."( 3-(2-aminoalkyl)-1-(2,6-difluorobenzyl)-5- (2-fluoro-3-methoxyphenyl)-6-methyl-uracils as orally bioavailable antagonists of the human gonadotropin releasing hormone receptor.
Bozigian, H; Chen, C; Chen, TK; Connors, PJ; Fisher, A; Gao, Y; Gross, TD; Guo, Z; Jin, L; Killam Bonneville, AL; Reinhart, GJ; Rowbottom, MW; Saunders, J; Struthers, RS; Tucci, FC; Xie, Q; Zhu, YF, 2004
)
0.55
" In this study, a pharmacokinetic model was developed, in an attempt to evaluate the bioavailability of FTD in these animals after the co-administration of TPI."( Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor.
Harashima, H; Kamiya, H; Kuwata, K; Nagayama, S; Tsuchiya, H; Yamashita, K, 2004
)
0.32
"The purpose of this investigation was to evaluate the effectiveness of oral 5-(phenylthio)acyclouridine (PTAU) in improving the pharmacokinetics and bioavailability of oral uridine."( 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Al Safarjalani, ON; El Kouni, MH; Naguib, FN; Rais, RH; Schinazi, RF; Shi, J; Zhou, XJ, 2005
)
0.54
" Coadministration of PTAU at 30, 45, 60, 120 and 240 mg/kg improved the low oral bioavailability (7."( 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Al Safarjalani, ON; El Kouni, MH; Naguib, FN; Rais, RH; Schinazi, RF; Shi, J; Zhou, XJ, 2005
)
0.54
"The excellent pharmacokinetic properties of PTAU, and its extraordinary effectiveness in improving the oral bioavailability of uridine, could be useful to rescue or protect from host toxicities of 5-fluorouracil and various chemotherapeutic pyrimidine analogues used in the treatment of cancer and AIDS, as well as in the management of medical disorders that are remedied by the administration of uridine including CNS disorders (e."( 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Al Safarjalani, ON; El Kouni, MH; Naguib, FN; Rais, RH; Schinazi, RF; Shi, J; Zhou, XJ, 2005
)
0.72
" The thymidine analog trifluorothymidine (TFT) has been shown to bypass resistance pathways for 5FU derivatives (S-1, UFT, Xeloda) in model systems, while concurrent application with a thymidine phosphorylase inhibitor (TPI) increases the bioavailability of TFT, thereby potentiating the in vivo efficacy of TFT."( Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
de Bruin, M; Emura, T; Fukushima, M; Peters, GJ; Temmink, OH, 2007
)
0.34
" VP-0502AL is predicted to become a new highly bioavailable anti-AIDS drug candidate and/or lead compound."( Bioavailability of the amino acid-attached prodrug as a new anti-HIV agent in rats.
Chae, KA; Cho, HJ; Kim, JS; Lee, H; Seo, DC; Shin, HC; Sung, JM, 2007
)
0.34
" Absolute oral bioavailability of alogliptin in rats, dogs, and monkeys was 45%, 86%, and 72% to 88%, respectively."( Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Asakawa, T; Christopher, RJ; Kassel, DB; Lee, B; Shi, L; Takeuchi, K, 2008
)
0.35
"All the (13)C-probes employed were well absorbed from the intestine after intraduodenal administration."( Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats.
Hirao, Y; Inada, M; Kashimoto, M; Kunizaki, J; Sato, H; Sugiyama, E; Tobita, K; Yoshida, T, 2009
)
0.61
" In this single-dose, randomized, two-way crossover study, we investigated the effects of a low-fat Japanese meal on the pharmacokinetics and oral bioavailability of UFT (2 x 100-mg capsules; dose in terms of tegafur) and leucovorin (1 x 25-mg tablet)."( Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer.
Furuhata, T; Hosokawa, Y; Ishiyama, G; Iwayama, Y; Kimura, Y; Meguro, M; Mizuguchi, T; Nishidate, T; Okita, K; Sasaki, K; Tsuruma, T, 2009
)
0.35
" It had lower oral absorption than salmeterol in rats, and lower bioavailability than salmeterol in vivo in both rats and dogs (2% and 5%, respectively)."( The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
Barrett, VJ; Bevan, NJ; Butchers, PR; Conroy, R; Emmons, A; Ford, AJ; Jeulin, S; Looker, BE; Lunniss, GE; Morrison, VS; Mutch, PJ; Perciaccante, R; Procopiou, PA; Ruston, M; Smith, CE; Somers, G, 2011
)
0.59
"Alogliptin is a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4)."( Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Erowele, G; Ndefo, UA; Okoli, O, 2014
)
0.4
" TAS-102 is an oral combination therapy consisting of trifluridine (FTD), a thymidine-based nucleoside analog, plus tipiracil hydrochloride (TPI), a novel thymidine phosphorylase inhibitor that improves the bioavailability of FTD."( TAS-102, a novel antitumor agent: a review of the mechanism of action.
Lenz, HJ; Loupakis, F; Stintzing, S, 2015
)
0.42
" GNMT expression in vivo improves folate retention and bioavailability in the liver."( Regulation of Folate-Mediated One-Carbon Metabolism by Glycine N-Methyltransferase (GNMT) and Methylenetetrahydrofolate Reductase (MTHFR).
Chiang, EP; Ko, HA; Lin, YJ; Tang, FY; Wang, YC; Wu, MT, 2015
)
0.42
" TPI is an inhibitor of TFD degradation enzyme thymidine phosphorylase and thus increases the bioavailability of TFD."( TAS-102 an Emerging Oral Fluoropyrimidine.
Chen, J; Han, M; Saif, MW, 2016
)
0.43
" Compound 13d, having good in vitro ADME profile and moderate oral bioavailability in mice, showed potent anti-inflammatory activity against hapten-induced contact hypersensitivity reaction in mice following topical and oral administration."( Synthesis and biological evaluation of novel orally available 1-phenyl-6-aminouracils containing dimethyldihydrobenzofuranol structure for the treatment of allergic skin diseases.
Fujiwara, N; Hasegawa, F; Inoue, Y; Isobe, M; Isobe, Y; Tobe, M; Tsuboi, K, 2016
)
0.66
" Maximum concentrations of both drugs decreased by approximately 40%, indicating that food influenced the absorption and bioavailability of trifluridine and tipiracil hydrochloride, respectively."( Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016
)
0.43
"Acid-reducing agents (ARAs) and proton-pump inhibitors (PPIs) that increase gastric pH can alter the bioavailability of antiviral drugs, particularly relevant in patients with advanced liver disease caused by chronic hepatitis C virus (HCV) infection seeking therapy."( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML, 2016
)
0.43
" The rapid degradation of TFT brought initial clinical development to a halt, but TFT reentered clinical trials when addition of a TPI was found to improve the bioavailability of TFT."( TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies.
Opdam, FL; van der Velden, DL; Voest, EE, 2016
)
0.43
" A phase 1 study evaluated relative bioavailability of TAS-102 tablets compared with an oral solution containing equivalent amounts of FTD and TPI."( A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.
Becerra, CR; Mizuguchi, H; Patel, M; Von Hoff, D; Yoshida, K, 2017
)
0.46
" Moreover, Caco-2/TC7 cells were exposed to the digested duodenal and colonic phases to elucidate the final bioavailability of CYN in an approximation to the real human exposure scenario."( Bioaccesibility of Cylindrospermopsin from cooked fish muscle after the application of an in vitro digestion model and its bioavailability.
Cameán, AM; Font, G; Jos, Á; Maisanaba, S; Meca, G; Saladino, F, 2017
)
0.46
"AZD3965, a pyrole pyrimidine derivative, is a potent and orally bioavailable inhibitor of monocarboxylate transporter 1 (MCT1), currently in a Phase I clinical trial in UK for lymphomas and solid tumors."( Development and validation of a liquid chromatography tandem mass spectrometry assay for AZD3965 in mouse plasma and tumor tissue: Application to pharmacokinetic and breast tumor xenograft studies.
Guan, X; Morris, ME; Ruszaj, D, 2018
)
0.48
" Mavacamten demonstrated low clearance, high volume of distribution, long terminal elimination half-life and excellent oral bioavailability cross-species."( In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin.
Brun, P; Carlson, TJ; Dick, R; Driscoll, JP; Erve, JCL; Evanchik, M; Grillo, MP; Haste, N; Markova, S, 2019
)
0.51
" Tipiracil blocks the degradation of trifluridine by thymidine phosphorylase, which improves the bioavailability of trifluridine and allows for oral administration."( The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan, BM; Hochster, HS; Lenz, HJ, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The absolute bioavailability of (R)-trelagliptin was identified to be 128."( The Chiral Bioconversion and Pharmacokinetic Analysis of Trelagliptin in Beagle Dog Plasma by LC-MS/MS.
Sun, L; Xi, W; Yu, J; Zhang, H; Zhou, L; Zou, Q, 2019
)
0.51
"Trifluridine/tipiracil (TT) is an orally administered combination of the thymidine-based nucleoside analogue trifluridine and the thymidine phosphorylase inhibitor tipiracil hydrochloride, which increases the bioavailability of cytotoxic trifluridine."( First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
Amellal, NC; André, T; Falcone, A; Fougeray, R; Gandossi, E; Kanehisa, A; Saunders, M, 2020
)
0.56
"Alogliptin (ALG), an inhibitor of dipeptidylpeptidase-4, is used in the management of type 2 diabetes mellitus, and has a high absorption rate (>60-71%), despite its low lipophilicity (logP=-1."( Intestinal Absorption of Alogliptin Is Mediated by a Fruit-Juice-Sensitive Transporter.
Abe, M; Ishii, M; Kikuchi, T; Morimoto, K; Ogihara, T; Oikawa, E; Sasaki, M; Tomita, M, 2021
)
0.62

Dosage Studied

5-fluorouracil (5-FU) and UFT were compared at equi-effective dosage levels against subcutaneous tumor of mouse colon 26. The urinary uracil value reflecting DPD activity of the whole body could be used as an index of recurrence at the time of long-term dosage of S-1.

ExcerptRelevanceReference
"5 to 250 mg/kg daily during five days), a significant augmentation of the phagocytic index being related to time and dosage was obtained in otherwise untreated mice."( [Effects of 6-methyl-uracil upon the phagocytic activity in mice following whole-body X-irradiation OR 2,4,6-triethyleneimino-s-triazine treatment (author's transl)].
Raake, W; Tempel, K, 1977
)
0.58
" We found that the 6AU sensitivity of the rpo21 mutants can be suppressed by increasing the dosage of the wild-type PPR2 gene, presumably as a result of overexpression of TFIIS."( Genetic interaction between transcription elongation factor TFIIS and RNA polymerase II.
Archambault, J; Friesen, JD; Lacroute, F; Ruet, A, 1992
)
0.28
" At each dosage level, semilogarithmic plots of concentration vs."( Elimination of the antiviral drug 5-ethyl-2'-deoxyuridine by the isolated perfused rat liver.
Joly, JM; Williams, WM,
)
0.13
" Dose-response curves and 50 and 90% inhibitory concentrations (IC50 and IC90, respectively) were determined for each drug."( Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.
Chamberland, S; Current, WL; Kirst, HA, 1991
)
0.28
" Since she complained of olfactory anesthesia at 2 months of treatment, the dosage of UFT was reduced to 2 capsules daily and the drug was withdrawn after another 2 months of treatment."( [Complete remission of lung metastases of bladder tumor treated by small dosage of UFT: a case report].
Fukuoka, H; Nomura, S; Ogawa, T; Sakanishi, S; Takeda, M, 1991
)
0.28
"A 58-year-old woman who was inoperable because of S3 (pancreas and colon) and P1 at the initial operation was treated with UFT, ADM and MMC at a dosage of 242."( [An unresectable gastric cancer radically resectable following UFT, ADM, MMC therapy].
Hayashi, S; Kamejima, N; Kasugai, T; Kataoka, M; Kureyama, Y; Masaoka, A; Mitsui, T; Taniwaki, S; Tsuji, H; Watarai, N, 1989
)
0.28
" However, increase in tegafur dosage volume did not correlate with 5-FU levels."( [5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur].
Arima, S; Futami, K; Kinashi, M; Shigeta, M; Shimura, H, 1986
)
0.27
" Total Ftorafur (FT) results using the same criteria from the UFT phase II study revealed, from a comparison of dosage and disease type, that UFT did not enhance FT side effects; rather, it markedly increases effectiveness."( [Report on nationwide pooled data and cohort investigation in UFT phase II study].
Kimura, K; Ota, K; Taguchi, T, 1987
)
0.27
" Although average values of the skin reaction after dosing were slightly lower compared to those before dosing in group B, sensitization was effective."( [Study on the preoperative adjuvant therapy of cancer--relation between serum and tumor tissue levels of UFT and OK-432 after administration, and skin reactions to Su-polysaccharide (Su-Ps)].
Ishikawa, M; Kumazawa, H; Rei, S; Saito, H, 1987
)
0.27
" Moreover, intratumoral concentration of 5-FU differed markedly even with the same administration method and dosage level."( [Anti-tumour effect of UFT on human renal cell carcinoma heterotransplanted into nude mice].
Furuta, M; Iizuka, N; Kondo, I; Machida, T; Masuda, F; Mori, Y; Nakada, J; Onishi, T; Suzuki, M, 1988
)
0.27
" Film- and stick-type implantable dosage forms of chitosan containing uracil were prepared by the 'Extrusion-in-Air' method."( Use of chitosan and hydroxypropylchitosan in drug formulations to effect sustained release.
Abe, M; Machida, Y; Nagai, T; Sannan, T, 1986
)
0.5
" Dose-response curves for its formation in [3H]thymidine-labeled DNA were constructed by exposing the DNA to increasing amounts of gamma-radiation and measuring the HMUra content."( Quantitative determination of the 5-(hydroxymethyl)uracil moiety in the DNA of gamma-irradiated cells.
Cadet, J; Cummings, A; Frenkel, K; Solomon, J; Steinberg, JJ; Teebor, GW, 1985
)
0.52
" Ara-A and IUdR, when administered intraperitoneally by several different dosage schedules, reduced the severity of cutaneous herpetic lesions and the incidence of paralysis and increased significantly the number of survivors."( Herpes simplex virus skin infection in hairless mice: treatment with antiviral compounds.
Brady, E; Friedman-Kien, AE; Klein, RJ, 1974
)
0.25
" Low dose and either continuous infusion or repetitive dosing of leucovorin, as well as the effect of treatment sequence and intervals between drugs, require additional investigation."( Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Allegra, CJ; Grogan, L; Sotos, GA, 1994
)
0.53
" After block of desensitization by concanavalin-A, dose-response analysis for activation of kainate-preferring receptors in DRG neurons gave the potency sequence trifluoromethyl > iodo > bromo approximately chloro > nitro approximately cyano > kainate > methyl > fluoro > (R,S)-AMPA >> willardiine; EC50 values for the most and least potent willardiine derivatives, 5-trifluoromethyl (70 nM) and 5-fluoro (69 microM), differed 1000-fold."( Willardiines differentiate agonist binding sites for kainate- versus AMPA-preferring glutamate receptors in DRG and hippocampal neurons.
Jane, DE; Mayer, ML; Watkins, JC; Wong, LA, 1994
)
0.29
" Dose-response characteristics of the inhibition were determined."( Cyclopentenyl uracil: an effective inhibitor of uridine salvage in vivo.
August, EM; Cysyk, RL; Malinowski, N; Marquez, V; Moyer, JD; Zaharevitz, D, 1995
)
0.65
"The dose-response curves for the inhibition of equilibrative uridine transport by dilazep, dipyridamole and nitrobenzylthioinosine (NBMPR) in undifferentiated HL-60 cells were biphasic."( Decrease in equilibrative uridine transport during monocytic differentiation of HL-60 leukaemia: involvement of protein kinase C.
Lee, CW, 1994
)
0.29
" After rats were orally dosed with 20 micrograms/kg 5-ethynyluracil, liver, intestinal mucosa, lung, and spleen DPD were inactivated by 83-94%."( 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo.
Harrington, JA; Porter, DJ; Spector, T, 1993
)
0.94
"Effects of 5-fluorouracil (5-FU) and UFT on an experimental liver metastasis model were compared at equi-effective dosage levels against subcutaneous tumor of mouse colon 26."( Effect of 5-fluorouracil and UFT on experimental liver metastasis model of colorectal cancer using mouse colon 26 cells.
Kosaki, G; Kurihara, M; Tominaga, T; Yoshida, Y, 1993
)
0.95
"In collaboration with 428 institutions nation-wide, comparative studies on the optimal daily dosage of UFT were carried out for non-curative resection cases of colorectal cancer for two years from January 1984 to December 1985."( [Cooperative Study of Surgical Adjuvant Chemotherapy for Colorectal Cancer (fourth report): five-year results after surgery].
Abe, O; Hattori, T; Inokuchi, K; Kikuchi, K; Komi, N; Kondo, T; Maehara, Y; Sugimachi, K; Taguchi, T; Uchino, J, 1993
)
0.29
"Netivudine dosing produces complete inhibition of plasma dihydropyrimidine dehydrogenase."( Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine.
Callaghan, J; Crome, P; Fraser, I; Frick, L; Peck, R; Posner, J; Wiggs, R; Wootton, R, 1996
)
0.54
"A combined phase I/II study (UFTM) of tegafururacil (UFT) and mitomycin C (MMC) was performed to find the optimal dosage for advanced colorectal cancer."( [Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer
Ikeda, E; Isomoto, H; Kato, T; Kodaira, S; Okuda, M; Takahashi, T; Teramoto, T; Yamamoto, Y, 1996
)
0.55
"To study the absolute bioavailability and pharmacokinetics of an oral solution of fluorouracil (5-FU) in patients treated with 776C85, an oral inactivator of dihydropyrimidine dehydrogenase (DPD), and to evaluate the feasibility of administering oral 5-FU and 776C85 on a multiple-daily dosing schedule."( Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Adjei, AA; Baker, SD; Donehower, RC; Doucette, M; Grochow, LB; Hohneker, JA; Khor, SP; Noe, DA; Rowinsky, EK; Sartorius, SE; Spector, T, 1996
)
0.75
" Multiple-daily dosing did not appear to affect the pharmacokinetics of oral 5-FU."( Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Adjei, AA; Baker, SD; Donehower, RC; Doucette, M; Grochow, LB; Hohneker, JA; Khor, SP; Noe, DA; Rowinsky, EK; Sartorius, SE; Spector, T, 1996
)
0.53
" In addition, 5-FU levels were detectable throughout the 28-day dosing period; however, there was no evidence of significant accumulation of uracil, tegafur, or 5-FU."( Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Pazdur, R, 1997
)
0.5
", in host tissues, such as bone marrow and gastrointestinal mucosa cells) due to inactivation of DPD in essentially all patients treated, permitting better 5-FU dosing guidelines."( Improving 5-FU with a novel dihydropyrimidine dehydrogenase inactivator.
Diasio, RB, 1998
)
0.3
" Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day."( Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996
)
0.52
" Weekly dosing of paclitaxel produces notable activity, while maintaining relatively low toxicity in heavily pretreated metastatic breast cancer patients."( UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.
Dethling, J; Kühnle, H; Lück, HJ; Scholz, U, 1999
)
0.3
"This phase I study was undertaken to define the maximum tolerated dose, dose-limiting toxicity, and recommended dosage of UFT (uracil and tegafur) plus oral calcium folinate (Orzel) and vinorelbine (Navelbine) in combination treatment of metastatic breast cancer in patients who have received one prior chemotherapy regimen."( UFT plus oral calcium folinate/vinorelbine for advanced breast cancer.
Déporte-Fety, R; Fumoleau, P; Kerbrat, P; Laguerre, B, 1999
)
0.51
" A comparison of the prescribed dosage and patient records revealed a mean dose rate of 86."( [UFT-E granule compliance in postoperative adjuvant chemotherapy].
Hagiwara, M; Hanai, A; Kanasugi, K; Komoriyama, H; Yamaguchi, S, 1999
)
0.3
" It was suggested that the pharmaceutical technology used in the manufacture was not equivalent even if the products of the same dosage form contain the same kind and content of the active ingredient(s)."( [Evaluation of dissolution behavior for the products containing tegafur and uracil].
Azuma, M; Houchi, H; Ichimaru, K; Ishiki, K; Kujime, T; Minakuchi, K; Shono, F; Umeda, T, 1999
)
0.53
" Four patients who suffered from PMC-related side effects of grade 1-2 wanted to decrease their dosage of UFT and/or 5-FU."( [Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report].
Izumi, S; Nakagawa, J; Nishihara, M; Onoda, Y; Shimizu, N; Shiota, K; Suzuka, I, 1999
)
0.3
" The results of both intraperitoneal (IP) and oral dosing of mice show that hepatotoxicity is the main effect of cylindrospermopsin in vivo, but that a thrombohemorrhagic phenomenon is observed in a proportion of dosed animals."( Cylindrospermopsin, a cyanobacterial alkaloid: evaluation of its toxicologic activity.
Lam, PK; Moore, MR; Seawright, AA; Shaw, GR, 2000
)
0.31
" In the second and third courses of the chemotherapy, CBDCA and TXT were administered in the same dosage as in the initial course, but with the oral administration of UFT (600 mg/day)."( [A case of epithelial cancer of the alveoli which responded favorably to the additional administration of UFT for refractory cancer after administration of carboplatin and docetaxel].
Kuwahara, M; Motohiro, A; Takahashi, N; Tsukamoto, S; Ueda, H, 2000
)
0.31
" The use of 5-FU pro-drugs and/or DPD inhibitors can overcome this absorption problem and allow for oral dosing of fluoropyrimidines."( Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
Hoff, PM; Pazdur, R, 1999
)
0.3
" The ratio of FBAL to 5-FU in Cmax and AUC after dosing of UFT was the lowest among these four test compounds."( [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Hirakawa, Y; Kawaguchi, Y; Kuwata, K; Matsushima, E; Nagayama, S, 2000
)
0.31
"UFT was administered orally at a dosage of 200 mg/day, 2 times a day, to patients over 80 years of age with oral cancer."( [5-FU concentration in the serum and the tumor tissue after administration of UFT 200 mg/day to patients over 80 years of age with oral cancer].
Fukuda, J; Hayatsu, M; Hoshina, H; Iida, A; Kaji, M; Miyamoto, T; Miyaura, Y; Nagashima, K; Ono, K; Takagi, R; Tsurumaki, H, 2000
)
0.31
" Prolonged oral dosing of 5-FU could mimic continuous infusion with less inconvenience and cost."( Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Kindler, HL; Schilsky, RL, 2000
)
0.87
" By temporarily eliminating this prevalent enzyme, eniluracil provides predictable dosing of 5-FU and enables oral administration of 5-FU to replace intravenous bolus and continuously infused dosing."( Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
Baccanari, DP; Cao, S; Davis, ST; Paff, MT; Rustum, YM; Spector, T; Tansik, RL, 2000
)
0.84
" In the presence of eniluracil, oral administration of 5-FU is feasible and variation in 5-FU exposure is reduced, with the anticipation of further reduction in variation as dosing guidelines based on renal function are formulated."( Pharmacology of fluorinated pyrimidines: eniluracil.
Baker, SD, 2000
)
0.87
" Eniluracil/5-FU has demonstrated efficacy as monotherapy in patients with a variety of solid tumors when given on a 5 or 28-day dosing schedule."( Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.
Hohneker, J; Levin, J, 2000
)
1.11
" This variability makes effective dosing of 5-FU and related drugs difficult."( Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio, RB, 2000
)
0.31
" The removal of one administration of vinorelbine at dose levels 3 and 4 has allowed for increased UFT dosage and AUC0-6 h of fluorouracil, with no dose-limiting toxicity reported for these patients."( UFT/leucovorin plus vinorelbine combination for advanced breast cancer.
Bonneterre, J; Déporte, R; Fargeot, P; Fumoleau, P; Kerbrat, P, 2000
)
0.51
"The recommended oral dosage of 5-FU (10 mg/m(2) PO bid) given with eniluracil and leucovorin is approximately 115-fold lower than the reference dosage for 24-hour infusional 5-FU."( Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Bi, DQ; Donavan, S; Grem, JL; Grollman, F; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Quinn, MG; Shapiro, J; Takimoto, CH; Zentko, S, 2000
)
0.79
" The rationale for developing a combined eniluracil/5-FU formulation oral dosing form is to simplify treatment with these agents, which has been performed using separate dosing forms, and decrease the probability of severe toxicity and/or suboptimal therapeutic results caused by inadvertently high or conversely insufficient 5-FU dosing."( Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Cohen, D; Drengler, R; Ertel, VP; Hoffman, C; Hsieh, A; Hurwitz, HI; Magnum, S; Monroe, P; Ochoa, L; Petros, WP; Rowinsky, EK; Schwartz, G; Thomas, JP; Wilding, G, 2000
)
0.8
"The trial was a randomized, three-way crossover bioequivalence study of three oral dosing forms of eniluracil/5-FU tablets in adults with solid malignancies."( Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Cohen, D; Drengler, R; Ertel, VP; Hoffman, C; Hsieh, A; Hurwitz, HI; Magnum, S; Monroe, P; Ochoa, L; Petros, WP; Rowinsky, EK; Schwartz, G; Thomas, JP; Wilding, G, 2000
)
0.75
" Both strengths of the combined eniluracil/5-FU dosing form and the separate dosing forms were bioequivalent."( Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Cohen, D; Drengler, R; Ertel, VP; Hoffman, C; Hsieh, A; Hurwitz, HI; Magnum, S; Monroe, P; Ochoa, L; Petros, WP; Rowinsky, EK; Schwartz, G; Thomas, JP; Wilding, G, 2000
)
0.81
" The availability of a combined eniluracil/5-FU oral dosing form will likely simplify dosing and decrease the probability of severe toxicity or suboptimal therapeutic results caused by an inadvertent 5-FU overdose or insufficient 5-FU dosing in the case of separate oral formulations, thereby enhancing the overall feasibility and 0therapeutic index of oral 5-FU therapy."( Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Cohen, D; Drengler, R; Ertel, VP; Hoffman, C; Hsieh, A; Hurwitz, HI; Magnum, S; Monroe, P; Ochoa, L; Petros, WP; Rowinsky, EK; Schwartz, G; Thomas, JP; Wilding, G, 2000
)
0.81
" Based on the feasibility and adverse reactions, the dosage of UFT should be set according to the body surface area at 375-425 mg/m2/day."( [Optimal dosage of UFT in a weekday-on/weekend-off schedule as a postoperative adjuvant chemotherapy for colorectal cancer].
Fukushima, T; Hiki, Y; Kumada, K; Makuuchi, H; Mitomi, T; Nagasaki, H; Nishiyama, K; Ohki, S; Otani, Y; Sadahiro, S; Shimada, H; Takahashi, T; Takemiya, S; Tsukikawa, S; Yamaguchi, S; Yamamura, T, 2000
)
0.31
" L(-)I-OddU is the most potent anti-Epstein-Barr Virus (EBV) compound without cytotoxicity and animal toxicity upon long-term dosing which gives the pharmacological levels of the drug in plasma."( Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers.
Cheng, YC, 2001
)
0.31
" After drug-induced hepatitis, a caffeine test might be used to check the total recovery or to choose an adapted dosage of medicines."( Caffeine metabolism differences in acute hepatitis of viral and drug origin.
Bechtel, PR; Bechtel, YC; Brientini, MP; David-Laroche, M; Lelouët, H; Miguet, JP; Paintaud, G,
)
0.13
" Phase I studies have been completed showing the tolerability of two dosing schedules, including (1) a chronic schedule with twice-daily administration of eniluracil plus oral fluorouracil (5-FU) (10:1 ratio) for 28 days, and (2) a schedule of eniluracil administered daily on days 1-7 with oral 5-FU once daily on days 2-6."( Oral eniluracil/5-FU for advanced colon and breast carcinomas.
Benson, AB, 2001
)
0.92
" These data suggest that UFT/leucovorin should not be dosed simultaneously with food."( Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001
)
0.31
" Information on each drug, such as the name of the drug, the dosage normally prescribed, and cost of treatment is listed."( What they say about: non-nucleoside drugs.
,
)
0.13
" The dosage of the oral clinical use for human cancer of 5-FU, HCFU, 5'-DFUR and UFT as tegafur (FT) is 200-300mg/d, 600mg/d, 800-1,200mg/d and 300-600mg/d respectively."( Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
Higashigawa, M; Kagawa, Y; Kakito, H; Kawasaki, H; Kojima, M; Ohkubo, T; Ooi, A; Sakurai, M, 2001
)
0.57
" This method can be useful to evaluate the activity of dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme of the chemotherapy drug fluoropyrimidine, which will be helpful in investigating subject variation of DPD and adjusting clinical dosage in pyrimidine chemotherapy."( Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry.
Hu, P; Hu, Y; Jiang, H; Jiang, J, 2002
)
0.61
"This study determined the effect of different weekly dosing schedules of 5-fluorouracil (5-FU)/leucovorin (LV)/eniluracil on dihydropyrimidine dehydrogenase (DPD) activity and plasma uracil levels."( Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Grem, JL; Guo, XD; Harold, N; Keith, B; Quinn, M; Schuler, B; Shapiro, J; Zentko, S, 2002
)
0.8
" The most appropriate dosing option appeared to be 400 mg x m(-2) per day of oral UFT for 14 consecutive days with 900 mg x m(-2) gemcitabine on days 8 and 15."( A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer.
Asoh, H; Ichinose, Y; Semba, H; Seto, T; Yamamoto, H; Yoh, K, 2002
)
0.31
" Patients were accrued at six different dosing combinations."( A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies.
Baker, MN; Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Levin, J; McGuirt, PV; Patton, JW; Willcutt, NT, 2002
)
0.56
" The treatment was interrupted if grade 3/4 toxicity appeared and was resumed at the same dosage on recovery."( Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial.
Antón-Torres, A; Aparicio, J; Aranda, E; Bretón, JJ; Carrato, A; Díaz-Rubio, E; Fernández-Martos, C; Navarro, M; Rivera, F; Sastre, J, 2001
)
0.69
" The treatment plan consisted of weekly gemcitabine for three weeks with twice daily dosing of 5-FU and eniluracil for 21 days beginning on day one of gemcitabine."( Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Alberti, D; Arzoomanian, RZ; Bailey, H; Berlin, JD; Binger, K; Feierabend, C; Marrocha, R; Morgan-Meadows, S; Mulkerin, D; Thomas, JP; Volkman, J; Wilding, G, 2002
)
0.85
" A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer."( Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002
)
0.55
" Body surface area-based dosing was statistically significantly associated with a reduction in interpatient variability in drug clearance for only five of the 33 agents: docosahexaenoic acid (DHA)-paclitaxel, 5-fluorouracil/eniluracil, paclitaxel, temozolomide, and troxacitabine."( Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
Baker, SD; Donehower, RC; Grochow, LB; Rowinsky, EK; Schellens, JH; Sparreboom, A; Verweij, J, 2002
)
0.5
"To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV)."( Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003
)
0.8
"A pharmacokinetic model for ftorafur and 5FU was developed and should be useful to further study drug interactions and establish dosing guidelines."( Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003
)
0.6
" Using the P53(def) transgenic mouse model male and female C57BL/6J hybrid mice were used to investigate potential cancer inducing effects from such oral dosing solutions."( Toxicological aspects of treatment to remove cyanobacterial toxins from drinking water determined using the heterozygous P53 transgenic mouse model.
Seawright, A; Senogles-Derham, PJ; Shahin, M; Shaw, G; Wickramisingh, W, 2003
)
0.32
" The 5-fluoro-uracil was given intravenously at a relatively nontoxic dosage level."( The potentiation of radiation effects with 5-fluoro-uracil.
FOYE, LV; HALL, B; ROTH, M; WILLETT, FM, 1960
)
0.85
" Administration of more than 2 courses was attempted for each patient, with the same dosage levels at all 3 scheduled steps."( [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K, 2004
)
0.32
"Eniluracil, an effective inactivator of dihydropyrimidine dehydrogenase, allows for oral dosing of 5-fluorouracil (5-FU), which avoids the morbidity of continuous infusion 5-FU."( A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004
)
1.16
" Also, food effect was assessed separately in a group dosed with 20 mg of the compound."( Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889.
Banken, L; Bellibas, SE; Brivet, B; Bush, ED; Chamorey, E; Kircher, C; Milano, G; Nave, S; Patel, I; Renée, N, 2004
)
0.32
"We evaluated the optimal dosage schedule for combined oral chemotherapy using uracil/tegafur (UFT) and leucovorin (LV) in Yoshida sarcoma-bearing rats."( Preliminary study of the optimal dosing schedule for oral UFT/leucovorin chemotherapy.
Ishikawa, K; Kamijo, A; Makuuchi, H; Murayama, C; Nakamura, T; Sadahiro, S; Saguchi, T; Suzuki, T; Yasuda, S,
)
0.36
"Administration of UFT/LV for 5 days of the week seemed to exhibit superior antitumor activity, with no increase in the incidence of adverse effects, as compared with the consecutive daily dosing schedule."( Preliminary study of the optimal dosing schedule for oral UFT/leucovorin chemotherapy.
Ishikawa, K; Kamijo, A; Makuuchi, H; Murayama, C; Nakamura, T; Sadahiro, S; Saguchi, T; Suzuki, T; Yasuda, S,
)
0.13
" Our hypothesis was that a relatively short and high dosage of TAS-102 results in an additional mechanism of FTD incorporation into DNA other than thymidylate synthase (TS) inhibition."( A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura, T; Fukushima, M; Ohshimo, H; Suzuki, N; Yamaguchi, M, 2004
)
0.32
" The suitability and robustness of the method for in vivo samples were confirmed by analysis of mouse plasma, muscle and tumour from animals dosed with 5-FU."( Hydrophilic interaction liquid chromatography-APCI-mass spectrometry determination of 5-fluorouracil in plasma and tissues.
Breda, M; Grassi, S; James, CA; Pisano, R, 2005
)
0.55
" It displays good pharmacokinetics when dosed in rats and dogs."( A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.
Chen, IW; Ellis, JD; Embrey, MW; Felock, PJ; Funk, TW; Gabryelski, LJ; Hazuda, DJ; Homnick, CF; Jin, L; Leonard, YM; Lin, JH; Moyer, G; Perlow, DS; Schleif, WA; Stillmock, KA; Tsou, NN; Vacca, JP; Wai, JS; Witmer, MV; Wong, BK; Young, SD; Zhuang, L, 2005
)
0.63
" Dose-response curves for glycerol and uracil indicated that weevil preference increased as sample concentration increased."( Chemically mediated host-plant selection by the milfoil weevil: a freshwater insect-plant interaction.
Gleason, FK; Marko, MD; Newman, RM, 2005
)
0.6
" It allows for oral dosing of 5-fluorouracil (5-FU), which may potentially improve the antitumor activity of 5-FU when delivered concurrently with radiotherapy while avoiding the inconvenience and morbidity of continuous infusion (CI) 5-FU."( A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
Cohen, DP; Czito, BG; Fernando, N; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Morse, MA; Pappas, TN; Petros, WP; Tyler, DS; Yu, D, 2006
)
0.92
" As a single agent, S-1 showed higher antitumor activity with its low intestinal toxicity compared to continuous venous infusion 5-FU, the most effective dosing method of 5-FU, and/or to clinically available oral fluoropyrimidines such as UFT, doxyfluridine and capecitabine on various murine tumors and human tumor xenografts."( [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima, M, 2006
)
0.33
"The developed model may be useful to optimize the dosage regimen of TS-1 under various clinical conditions."( Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Hori, S; Inoue, S; Ohtani, H; Sawada, Y; Tsujimoto, M, 2007
)
0.34
" A dosage of 335 mg/m2/day of UFT was given perorally on daily schedule."( Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.
Akagi, Y; Fukushima, T; Ishibashi, N; Mori, S; Murakami, H; Ogata, Y; Shirouzu, K; Ushijima, M, 2007
)
0.34
" On day 14, mean peak DPP-4 inhibition ranged from 94% to 99%, and mean inhibition at 24 hours after dosing ranged from 82% to 97% across all alogliptin doses."( Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Mekki, QA; Wann, ER, 2008
)
0.35
" The PK and PD profiles of multiple doses of alogliptin in this study supported use of a once-daily dosing regimen."( Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Mekki, QA; Wann, ER, 2008
)
0.35
" Blood and urine were collected over 72 hours after dosing for pharmacokinetic analysis and determination of plasma DPP-4 inhibition and active glucagon-like peptide -1(GLP-1) concentrations."( Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Mekki, QA; Wann, ER, 2008
)
0.35
" Across alogliptin doses, mean peak DPP-4 inhibition ranged from 93% to 99%, and mean inhibition at 24 hours after dosing ranged from 74% to 97%."( Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Mekki, QA; Wann, ER, 2008
)
0.35
"This study was designed to determine the safety and optimal dosing of TAS-102, a novel oral combination of alphaalphaalpha-trifluorothymidine (FTD) and an inhibitor of thymidine phoshorylase, in patients with solid tumors."( Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
Abbruzzese, JL; Fukushima, M; Hoff, PM; Kopetz, S; Kuwata, K; Mita, A; Overman, MJ; Thomas, MB; Varadhachary, G; Wolff, RA; Xiong, H, 2008
)
0.35
" In summary, these data suggest that alogliptin is a potent and highly selective DPP-4 inhibitor with demonstrated efficacy in Zucker fa/fa rats and potential for once-daily dosing in humans."( Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Asakawa, T; Christopher, RJ; Kassel, DB; Lee, B; Shi, L; Takeuchi, K, 2008
)
0.35
" The urinary uracil value reflecting DPD activity of the whole body could be used as an index of recurrence at the time of long-term dosage of S-1."( [Study of a relationship between a change in the urinary uracil value after a S-1 long-term administration and the recurrence of stomach cancer].
Akiyama, I; Fujita, Y; Hasegawa, K; Morimoto, S; Shono, Y; Tabuse, K; Tsuji, T, 2008
)
0.96
" The PBPK and PD models were combined, and various dosing strategies were tested."( A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration.
Dhiman, A; Shuler, ML; Sung, JH, 2009
)
0.35
" GEM was administrated at a dosage of 1 g/m(2) intravenously weekly 3 of 4 weeks and UFT at a dosage of 200 mg/day orally continuously."( A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Furukawa, K; Ito, H; Kato, A; Kimura, F; Miyazaki, M; Nozawa, S; Otsuka, M; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H, 2008
)
0.59
"Any sampling interval at least 4 h after caffeine dosing is suitable for NAT2 and XO activity assessments."( Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
Fuhr, U; Jetter, A; Kinzig, M; Rodamer, M; Sörgel, F; Tomalik-Scharte, D, 2009
)
0.35
"Etoposide 50 mg/m(2), UFT 250 mg/m(2) and leucovorin 90 mg (fixed dose) were dosed in 3 gifts approximately 8h apart for 14 days followed by 1 week rest every 3 weeks until progressive disease (PD)."( Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R, 2009
)
0.35
" If an appropriate DIF product is selected and its dosage set based on the patient's urinary uracil value, the occurrence of side effects would be reduced."( [Significance of urinary uracil measurement following administration of DPD inhibitory fluoropyrimidine(DIF)products].
Akiyama, I; Fujita, Y; Hasegawa, K; Horiuchi, T; Miyabe, T; Nakajima, Y; Shono, Y; Tabuse, K; Uchida, K, 2009
)
0.88
" In a nonrandomized, single-sequence study (study II), participants (n = 24 completed) received a single 5-mg dose of the sulfonylurea glyburide, alone and after 8 days of dosing with alogliptin 25 mg qd."( Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Fleck, P; Karim, A; Laurent, A; Mekki, Q; Munsaka, M; Wann, E, 2009
)
0.35
"9%, respectively, compared with dosing on an empty stomach."( Effects of a low-fat meal on the oral bioavailability of UFT and leucovorin in patients with colorectal cancer.
Furuhata, T; Hosokawa, Y; Ishiyama, G; Iwayama, Y; Kimura, Y; Meguro, M; Mizuguchi, T; Nishidate, T; Okita, K; Sasaki, K; Tsuruma, T, 2009
)
0.35
" Although eniluracil in combination with 5-FU was promising in phase I and II studies, in 2 multicenter phase III colorectal cancer studies, eniluracil dosed in a 10-to-1 ratio to 5-FU produced less antitumor benefit than the standard regimen of 5-FU/leucovorin without eniluracil."( A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil.
Cao, S; Spector, T, 2010
)
0.96
" When chemotherapy with S-1 or UFT/LV started from the micrometastasis stage, not the advanced macroscopic metastasis stage, anti-LNM efficacy of S-1 was significantly higher than that of UFT/LV at the dosage in which antitumor activity of the two drugs against primary subcutaneous tumor was comparable."( Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/ LV.
Hirai, T; Ito, Y; Kato, T; Kodera, Y; Nakanishi, H; Nakao, A, 2010
)
0.36
" The regimen of pre-op CCRT was a radiation dosage of 45  Gy in 20 fractions and oral tegafur-uracil (UFUR) and leucovorin."( The impact of preoperative chemoradiotherapy on advanced low rectal cancer.
Chang, SC; Chen, WS; Jiang, JK; Kao, PS; Lee, RC; Liang, WY; Lin, JK; Lin, TC; Wang, HS; Wang, LW; Yang, SH, 2010
)
0.58
" In the Phase I part, dose-limiting toxicities occurred in all three patients, given mitoxantrone at the dosage of 10 mg/m(2)/day, and the recommended mitoxantrone dosage was determined to be 8 mg/m(2)/day."( A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.
Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011
)
0.61
" Therefore, we reduced the administration dosage to 60 mg/ day."( [An elderly patient with advanced gastric cancer maintaining complete response for over 3 years by oral administration of UFT following short span of S-1].
Baba, H; Beppu, T; Okabe, K; Sano, O; Sugiyama, S; Wada, A; Yamanaka, T, 2010
)
0.36
" Based on preclinical evidence, we aimed at studying a new dosing schedule for the combination with sequential administration, a lower dose of EU and higher doses of 5-FU than previously investigated."( Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma.
Chang, AY; de Lima Lopes, G; Dicksey, JS; Palalay, M; Peters, WP, 2011
)
0.61
"These cases suggest that 5-FU standard dosage administration may lead to strong overexposure, responsible for the severe toxicities observed, including the neurological features."( 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Ciccolini, J; Cordier, PY; Lacarelle, B; Mercier, C; Nau, A; Oliver, M; Peytel, E, 2011
)
0.37
" Repeated uracil dosing showed reproducible uracil PK in subjects with normal DPD status, and dose elevation of uracil suggested linear pharmacokinetics."( Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.
Guchelaar, HJ; Maring, JG; Theeuwes-Oonk, B; van Kuilenburg, AB; van Staveren, MC, 2011
)
1.04
" Patients had an option to continue in a 40-week, open-label extension study, with those originally randomized to alogliptin remaining on the same dosage regimen while patients treated with placebo were randomly allocated to alogliptin 12."( Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Hirayama, M; Hiroi, S; Itayasu, T; Kaku, K; Seino, Y, 2011
)
0.37
" An improved method for measuring the absorbed fraction of analogues dosed to rats, which considers the glucuronidated fraction is presented."( The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.
Barrett, VJ; Bevan, NJ; Butchers, PR; Conroy, R; Emmons, A; Ford, AJ; Jeulin, S; Looker, BE; Lunniss, GE; Morrison, VS; Mutch, PJ; Perciaccante, R; Procopiou, PA; Ruston, M; Smith, CE; Somers, G, 2011
)
0.59
" The objective of this model-based meta-analysis was to describe the time course of HbA1c response after dosing with alogliptin (ALOG), saxagliptin (SAXA), sitagliptin (SITA), or vildagliptin (VILD)."( Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B, 2012
)
0.38
" Combined quantification of U and UH(2) with 5-FU and 5-FUH(2) may provide a pre-therapeutic assessment of DPD activity and further guide drug dosing during therapy."( LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
Amstutz, U; Büchel, B; Bühr, C; Largiadèr, CR; Rhyn, P; Schürch, S, 2013
)
0.65
" The X-ray crystallography studies have been revealed that Alogliptin binds to DPP-IV active site by non-covalently and provides sustained reduction of plasma DPP-IV activity as well as lowering of blood glucose, in drug-naive patients with T2DM and inadequate glycemic control, once daily oral dosing regimen with varying levels of doses ranging from 25-800 mg."( Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
Agrawal, R; Bahare, RS; Dikshit, SN; Ganguly, S; Jain, P, 2012
)
0.38
" In the present study we estimated radiation dose-response curves for various grades of tumor regression after preoperative CRT."( Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.
Appelt, AL; Bentzen, SM; Jakobsen, A; Pløen, J; Vogelius, IR, 2013
)
0.39
" The radiation dose-response relationship for a specific grade of histopathologic tumor regression was parameterized in terms of the dose required for 50% response, D50,i, and the normalized dose-response gradient, γ50,i."( Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.
Appelt, AL; Bentzen, SM; Jakobsen, A; Pløen, J; Vogelius, IR, 2013
)
0.39
"A highly significant dose-response relationship was found (P=."( Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.
Appelt, AL; Bentzen, SM; Jakobsen, A; Pløen, J; Vogelius, IR, 2013
)
0.39
"This study demonstrated a significant dose-response relationship for tumor regression after preoperative CRT for locally advanced rectal cancer for tumor dose levels in the range of 50."( Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.
Appelt, AL; Bentzen, SM; Jakobsen, A; Pløen, J; Vogelius, IR, 2013
)
0.39
" In CRC patients receiving proper dosing regimens, plasma UH2/Ura could be an indirect biomarker for predicting 5-FU treatment efficacy, tumor growth, and 5-FU doses."( Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer.
Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013
)
0.65
" In addition to an appropriate dosing regimen, pretherapeutic assessment of the UH2/Ura ratio in the plasma of CRC patients and PK/PD analysis with the plasma UH2/Ura ratio could enable the development of an optimal therapeutic scheme for each patient."( Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013
)
0.64
" The main differences between the five gliptins on the market include: potency, target selectivity, oral bioavailability, long or short half-life, high or low binding to plasma proteins, metabolism, presence of active or inactive metabolites, excretion routes, dosage adjustment for renal and liver insufficiency, and potential drug-drug interactions."( Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
Capuano, A; Esposito, K; Giugliano, D; Maiorino, MI; Rossi, F; Sportiello, L, 2013
)
0.39
" Dose-response data suggested about the same range of toxicity of FBS and FLI samples (EC50  = 0."( Pharmacological studies confirm neurotoxic metabolite(s) produced by the bloom-forming Cylindrospermopsis raciborskii in Hungary.
Farkas, A; Győri, J; Kovács, AW; Szabó, H; Vasas, G; Vehovszky, Á, 2015
)
0.42
" Alogliptin does not require any dosage adjustment when coadministered with ketoconazole, fluconazole, gemfibrozil, warfarin, metformin, glyburide, and pioglitazone."( Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Erowele, G; Ndefo, UA; Okoli, O, 2014
)
0.4
" In each treatment group, the baseline characteristics including age, gender, body mass index, diabetes duration, HbA1c, fasting plasma glucose, body weight, daily dosage of metformin and daily dosage of pioglitazone were all well balanced."( [The design and baseline characteristics of a phase III study to evaluate the efficacy and safety of alogliptin versus placebo in type 2 diabetes mellitus in Mainland China].
Bu, RF; Gu, W; Han, P; Ji, QH; Jiang, ZS; Lei, MX; Li, CJ; Li, L; Li, WH; Li, XF; Li, XJ; Li, ZF; Liu, JD; Liu, XM; Liu, Y; Liu, ZM; Lu, JM; Lü, XF; Pan, CY; Peng, YD; Qu, S; Shi, BY; Song, QH; Xu, XJ; Xue, YM; Yan, L; Yang, JK; Zeng, JE; Zheng, BZ, 2013
)
0.39
"Oral UFT plus leucovorin given by either dosage schedule is a very safe regimen for adjuvant chemotherapy."( Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.
Baba, H; Hamada, C; Kakeji, Y; Katsumata, K; Koda, K; Kodaira, S; Kondo, K; Matsuoka, J; Morita, T; Nishimura, G; Sadahiro, S; Saji, S; Sasaki, K; Sato, S; Tsuchiya, T; Usuki, H; Yamaguchi, Y, 2014
)
0.66
" Study animals were administered 50 μg/kg CYN once daily by ip route and euthanized 24 h after 1, 2, 3, 4, or 5 consecutive doses, or 6 or 13 d after the dosing period."( The course of toxicity in the pregnant mouse after exposure to the cyanobacterial toxin cylindrospermopsin: clinical effects, serum chemistries, hematology, and histopathology.
Brix, A; Chernoff, N; Gage, MI; Hill, D; Malarkey, DE; Rogers, EH; Schmid, JE; Travlos, GS; Zehr, RD, 2014
)
0.4
" Thirteen studies were conducted to characterize drug-drug interactions for the 3D regimen of OBV, PTV/r, and DSV and various medications in healthy volunteers to inform dosing recommendations in HCV-infected patients."( Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Awni, WM; Badri, PS; Coakley, EP; Dutta, S; Hu, B; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Wang, T; Zha, J, 2015
)
0.42
" The results suggest that cyclosporine and tacrolimus doses and dosing frequency should be reduced in HCV-infected posttransplant patients being treated with this 3-DAA regimen."( Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.
Awni, W; Badri, P; Bernstein, B; Coakley, E; Cohen, D; Ding, B; Dutta, S; Menon, R; Podsadecki, T, 2015
)
0.42
" The toxic effects of CYN on the samples are greatly influenced by the TiO2 dosage and reaction time, possibly yielding by-products that may change the mutagenic properties of CYN."( Degradation of cyanotoxin cylindrospermopsin by TiO2-assisted ozonation in water.
Huang, WJ; Ji, BH; Wu, CC, 2015
)
0.42
" Due to the convenient dosing regimen, it is expected to be widely used in the clinical setting."( First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.
Kaku, K, 2015
)
0.42
"Standard methods for meta-analysis of dose-response data in epidemiology assume a model with a single scalar parameter, such as log-linear relationships between exposure and outcome; such models are implicitly unbounded."( Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin.
Aronson, JK; Langford, O; Stevens, RJ; van Valkenhoef, G, 2018
)
0.48
"Among 2,053 patients enrolled and dosed with study drug, 410 (20%) were receiving concomitant ARAs; of these, 308 (15%) were taking concomitant PPIs."( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML, 2016
)
0.43
" The results suggested an influence of circadian rhythms on phenotype-guided fluoropyrimidine dosing and supported implications for chronotherapy with high-dose fluoropyrimidine administration during the night."( Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.
Beijnen, JH; Burylo, AM; Cats, A; de Vries, N; Deenen, MJ; Huitema, AD; Jacobs, BA; Krähenbühl, MD; Meulendijks, D; Pluim, D; Rosing, H; Schellens, JH; van Geel, RM; van Hasselt, JG, 2016
)
0.43
" Moreover, we recommend that, for patients with repeated treatment postponement due to neutropenia, the dosage should be fixed based on therapeutic efficacy and prognosis."( Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016
)
0.43
" The success of these dosing recommendations was evaluated by analyzing pharmacokinetic data from liver transplant recipients in the CORAL-I study."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"A population pharmacokinetic model was developed using tacrolimus dosing and Ctrough data before and during 3D treatment (n = 29)."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"Observed data for tacrolimus and CSA in liver transplant recipients confirm that the recommended dosing strategies are valid and therapeutic levels of immunosuppression can be maintained during 3D treatment."( Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A, 2016
)
0.43
"Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients."( Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.
Grimshaw, CE; Jennings, A; Kamran, R; Kinugawa, Y; Kosaka, T; Koumura, E; Nishigaki, N; Sano, H; Shi, L; Takeuchi, K; Tani, A; Ueno, H, 2016
)
0.43
"Overall, 24 subjects, six in each of four renal function groups (normal, mild, moderate, and severe), received a single dose of the 3D and 2D regimens in separate dosing periods."( Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
Awni, WM; Dutta, S; Khatri, A; Marbury, TC; Menon, RM; Preston, RA; Rodrigues, L; Wang, H, 2017
)
0.46
" It can be postulated that the dosage of TAS-102 potentially may need to be increased to achieve better outcomes in patients not experiencing any neutropenia."( Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Cecchini, M; Grothey, A; Hochster, HS; Kasi, PM; Kotani, D; Ohtsu, A; Ramanathan, RK; Shitara, K; Yoshino, T, 2016
)
0.43
" This prescribing could have been due to the complexity of different dosing requirements, or a lack of awareness of the need for dose adjustment of most DPP-4 inhibitors in patients with renal impairment."( Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Bingham-Gardiner, P; Bolodeoku, J; Hassan, SW; Lee, S; Scowcroft, A; Spencer, W; Tebboth, A, 2016
)
0.43
" On the basis of the relationship shown, changes in clinical efficacy in association with dose change were examined in order to discuss clinical dosage from the standpoint of proper usage."( Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics.
Kimura, K; Takayanagi, R; Uchida, T; Yamada, Y, 2017
)
0.46
" In the phase II/III clinical studies, ALT and bilirubin increases were reversible with continued dosing or after treatment cessation."( Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
Awni, W; DaSilva-Tillmann, B; Dutta, S; Lin, CW; Liu, W; Menon, R; Podsadecki, T; Shulman, N, 2017
)
0.46
" The optimized methods were compared using one-way analysis of variance (ANOVA) and proved to be accurate for assay of the investigated drugs in their pharmaceutical dosage form."( Comparative study between different simple methods manipulating ratio spectra for the analysis of alogliptin and metformin co-formulated with highly different concentrations.
Ayoub, BM; Hassan, MA; Mowaka, S; Zaghary, WA, 2017
)
0.46
" Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D."( Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.
Bellissant, E; Ben Ali, Z; Boglione-Kerrien, C; Guyader, D; Jezequel, C; Lemaitre, F; Tron, C; Verdier, MC, 2017
)
0.46
" As trelagliptin only requires dosing once per week, this new agent has the potential to improve compliance and subsequently, glycaemic control, in patients with T2DM."( Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients.
Kaku, K, 2017
)
0.46
" RBV was dosed by physician discretion between 200 mg weekly and 200 mg daily."( High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM, 2018
)
0.48
" Dose-response curves following single intraperitoneal injections of purified CYN (at 0, 16, 32, 64 and 128 μg CYN/kg body weight) were created in 10-week-old male BALB/C mice (n = 4)."( Renal tubular damage caused by cylindrospermopsin (cyanotoxin) in mice.
Magalhães, VF; Moraes, ACN, 2018
)
0.48
" We describe the clinical management of ribavirin dosing in hepatitis C virus-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin."( Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Bernstein, DE; Feld, JJ; Ferenci, P; Larsen, L; Tatsch, F; Vlierberghe, HV; Younes, Z, 2018
)
0.48
" The proposed method is applicable for the analysis of six pharmaceutical dosage forms namely, Nesina®, Actos®, Glucophage®, Oseni®, Kazano® and Actoplus MET® tablets."( A guide for using experimental design in chromatographic method development: applied to the analysis of selected anti-diabetic pharmaceutical combinations.
Abdel-Aziz, O; Ayoub, BM, 2016
)
0.43
"5%) patients (calcium channel blockers, ACE inhibitors, statins, diuretics, tacrolimus); four patients required further adjustment of antihypertensive drugs or tacrolimus dosage on-treatment."( Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.
Chmelova, K; Frankova, S; Kreidlova, M; Merta, D; Senkerikova, R; Sperl, J, 2018
)
0.48
" At the end of the dosing period, examinations of animals noted (1) elevated organ to body weight ratios of liver and kidney at all dose levels, (2) treatment-related increases in serum alanine aminotransferase (ALT) activity, (3) decreased blood urea nitrogen (BUN) and cholesterol concentrations in males, and (4) elevated monocyte counts in both genders."( Cylindrospermopsin toxicity in mice following a 90-d oral exposure.
Chernoff, N; Chorus, I; Diggs, DL; Hill, DJ; Huang, H; King, D; Lang, JR; Le, TT; Schmid, JE; Travlos, GS; Whitley, EM; Wilson, RE; Wood, CR, 2018
)
0.48
" Hence, sludge should be treated within 4 d and excess PAFC dosing should be avoided."( Worse than cell lysis: The resilience of Oscillatoria sp. during sludge storage in drinking water treatment.
Jin, Y; Li, H; Ma, C; Pei, H; Sun, J; Xu, H, 2018
)
0.48
" The current study objectives were to assess the preclinical pharmacokinetics of mavacamten for the prediction of human dosing and to establish the potential need for clinical pharmacokinetic studies characterizing drug-drug interaction potential."( In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin.
Brun, P; Carlson, TJ; Dick, R; Driscoll, JP; Erve, JCL; Evanchik, M; Grillo, MP; Haste, N; Markova, S, 2019
)
0.51
" These findings show that, when assessing plasma uracil and dihydrouracil levels for adaptive fluoropyrimidine dosing in clinical practice, sampling should be done between 8:00 h and 9:00 h after overnight fasting to avoid bias caused by circadian rhythm and food effects."( Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.
Beijnen, JH; Cats, A; de Vries, N; Guchelaar, HJ; Henricks, LM; Huitema, ADR; Jacobs, BAW; Meulendijks, D; Pluim, D; Rosing, H; Schellens, JHM; van den Broek, D, 2018
)
1.05
" This Phase I, open-label, nonrandomized study investigated the safety, tolerability and pharmacokinetics of FTD/TPI in patients with advanced solid tumours (except breast cancer) and varying degrees of hepatic impairment, to provide dosing recommendations."( Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Bebeau, P; Becerra, C; Rosen, L; Rudek, MA; Saif, MW; Shepard, DR; Sun, W; Winkler, R; Yamashita, F, 2019
)
0.51
"Regorafenib at different dosing strategies and TAS-102 are treatment options for refractory metastatic colorectal cancer (mCRC)."( A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer.
Ahn, DH; Bekaii-Saab, T; Benkhadra, R; Firwana, B; Hubbard, JM; Mody, K; Murad, MH; Sonbol, MB; Walden, DJ; Wang, Z, 2019
)
0.51
" Individualized dosing for these patients can reduce the incidence of severe fluoropyrimidine-related toxicity."( Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
Beijnen, JH; Cats, A; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Knikman, JE, 2021
)
0.62
" Treatment with GC-1 upregulated the transcription of CPT1A in the human hepatocyte-derived Huh-7 cell line with a dose-response comparable to that of the native THR ligand, triiodothyronine (T3)."( Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
Beigelman, LN; Blatt, LM; Chanda, S; Deval, J; Gupta, K; Jekle, A; Lin, TI; Luong, XG; McGowan, D; Misner, D; Mukherjee, S; Raboisson, P; Stevens, SK; Stoycheva, A; Symons, JA; Vandyck, K; Williams, C, 2020
)
0.56
" The patient received several courses of chemotherapy with adjustments of the dose and dosing intervals to prevent neutropenia."( [Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
Amagasa, H; Ami, K; Ando, M; Fukuda, A; Gan, S; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kawaguchi, M; Maeda, F; Motoyama, K; Okano, Y; Tokitou, F; Yamada, A, 2021
)
0.62
" Until the findings are confirmed in clinical drug interaction studies, APAP dosage should not exceed 3 g per day in dasabuvir-treated patients to avoid potentially hepatotoxic APAP exposures."( Mechanism of dasabuvir inhibition of acetaminophen glucuronidation.
Duan, SX; Greenblatt, DJ; Harmatz, JS; Singleton, CA; Wei, Z; Zhang, Q, 2022
)
0.72
"To analyze alogliptin in its pharmaceutical dosage forms and human plasma, a sensitive, inexpensive, simple, and precise spectrofluorimetric method was developed and tested."( Hantzsch condensation reaction as a spectrofluorometric method for determination of alogliptin, an antidiabetic drug, in pure form, tablet form, and human and rat plasma.
Gahlan, AA; Haredy, AM; Taher, MA; Tammam, AS, 2022
)
0.72
"The clinical guidelines suggest that the dosing of cyclosporine (CsA), during combination therapy with paritaprevir/ritonavir-ombitasvir and dasabuvir (PrOD), would be only one-fifth of the pre-PrOD total daily dose to be administered once daily."( Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022
)
0.72
" The authors proposed reducing the CsA dosage during PrOD treatment to one-seventh of that of the pre-PrOD treatment of the total daily dose to maintain target CsA levels."( Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022
)
0.72
" Although the evidence for genotype-directed dosing of fluoropyrimidines is substantial, the level of evidence supporting plasma uracil levels to predict DPD activity in clinical practice is limited."( Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
Beijnen, JH; Cats, A; de Man, FM; de Vries, N; de With, M; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Imholz, ALT; Knikman, J; Lunenburg, CATC; Maring, JG; Mathijssen, RHJ; Meulendijks, D; Modak, A; Pluim, D; Rosing, H; Schellens, JHM; Swen, JJ; van Kuilenburg, ABP; van Schaik, RHN; van Staveren, MC, 2022
)
1.17
" Tolerance was good and 5-FU dosing was next shifted to 25% reduction, then further shifted to normal dosing at the 5th course, with still no sign for drug-related toxicities."( Renal impairment and DPD testing: Watch out for false-positive results!
Carriat, L; Ciccolini, J; Quaranta, S; Rony, M; Solas, C, 2022
)
0.72
"This study aimed to build a mathematical model of physiologically based pharmacokinetic combined DPP-4 occupancy (PBPK-DO) in humans to provide some recommendations for dosing adjustment in patients with renal impairment."( Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling.
Li, B; Liu, H; Liu, Y; Ren, C; Wang, G; Wu, C; Yu, S; Zhang, J, 2022
)
0.72
"The present PBPK-DO model can simultaneously predict PK and PD of TRE and OMA in humans and also provide valuable recommendations for dosing adjustment in renal impairment patients, which cannot be achieved by alone depending on PK change."( Prediction of pharmacokinetics and pharmacodynamics of trelagliptin and omarigliptin in healthy humans and in patients with renal impairment using physiologically based pharmacokinetic combined DPP-4 occupancy modeling.
Li, B; Liu, H; Liu, Y; Ren, C; Wang, G; Wu, C; Yu, S; Zhang, J, 2022
)
0.72
" Moreover, the use of advanced techniques would aid in deciphering cyanotoxins dose-response relationships in relation to their ED potential."( Potential Endocrine Disruption of Cyanobacterial Toxins, Microcystins and Cylindrospermopsin: A Review.
Cameán, AM; Casas-Rodriguez, A; Jos, A, 2022
)
0.72
"8% of DPYD variant carriers died due to FP-TOX compared to 0% in the group receiving DPYD genotype-guided dosing of FP."( Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
Bergmann, TK; Damkier, P; Ewertz, M; Feddersen, S; Fruekilde, PBN; Holm, HS; Paulsen, NH; Pfeiffer, P; Qvortrup, C, 2023
)
0.91
" Although dosage determination criteria according to plasma drug concentrations are required, the relationship between pharmacokinetics and drug response after multiple oral 5-FU derivative administrations remain unknown."( A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023
)
1.16
"Plasma 5-FU exposure levels increased with the dosing time, and large variations were observed in tumor 5-FU concentrations (32."( A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023
)
1.16
"In this phase Ib study MODURATE, we optimized the dosing schedule and tested the efficacy and safety of trifluridine/tipiracil, irinotecan, and bevacizumab in patients with metastatic colorectal cancer with fluoropyrimidine and oxaliplatin treatment failure."( Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Daphnia magna metaboliteA Daphnia metabolite produced by the species Daphnia magna.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrimidine nucleobaseA nucleobase whose skeleton is derived from pyrimidine.
pyrimidoneA pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (64)

PathwayProteinsCompounds
Metabolism14961108
Nucleotide metabolism89125
Nucleotide salvage2128
Pyrimidine salvage913
Nucleotide catabolism3671
Pyrimidine catabolism1025
DNA Repair25547
Base Excision Repair3523
Base-Excision Repair, AP Site Formation1716
Depyrimidination159
Cleavage of the damaged pyrimidine109
Pyrimidine Metabolism2353
beta-Alanine Metabolism927
GABA-Transaminase Deficiency927
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Ureidopropionase Deficiency927
Carnosinuria, Carnosinemia927
Purine Degradation28
Pyrimidine Ribonucleosides Degradation511
Uracil Degradation III616
Salvage Pathways of Pyrimidine Deoxyribonucleotides514
Pyrimidine Deoxyribonucleosides Degradation410
pseudouridine degradation08
pyrimidine nucleobases salvage I24
willardiine and isowillardiine biosynthesis010
superpathway of pyrimidine ribonucleosides salvage720
lathyrine biosynthesis07
uracil degradation I (reductive)211
superpathway of pyrimidine nucleobases salvage514
pyrimidine ribonucleosides salvage II27
pyrimidine salvage pathway311
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
Uridine + Orthophosphate = Uracil + D-Ribose 1-phosphate ( Pyrimidine Nucleotides and Nucleosides metabolism )13
NADP+ + 5,6-Dihydro-uracil = NADPH + Uracil ( Pyrimidine Nucleotides and Nucleosides metabolism )14
Deoxy-uridine + Orthophosphate = 2-Deoxy-D-ribose 1-phosphate + Uracil ( Pyrimidine Nucleotides and Nucleosides metabolism )14
Biomarkers for pyrimidine metabolism disorders1432
Urea cycle and associated pathways2430
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
pyrimidine nucleobases salvage II08
Smith-Magenis and Potocki-Lupski syndrome copy number variation1399
uracil degradation310
pyrimidine ribonucleosides degradation513
uracil degradation I (reductive)919
pyrimidine deoxyribonucleosides degradation714
superpathway of pyrimidine deoxyribonucleosides degradation738
pseudouridine degradation29
nucleoside and nucleotide degradation (archaea)722
pyrimidine ribonucleosides salvage III613
pyrimidine nucleobases salvage I38
superpathway of pyrimidine ribonucleosides salvage2237
pyrimidine nucleobases salvage II418
pyrimidine ribonucleosides salvage II812
superpathway of pyrimidine nucleobases salvage1126
uracil degradation II (oxidative)112
uracil degradation III416
superpathway of pyrimidine ribonucleosides degradation1317
willardiine and isowillardiine biosynthesis011
lathyrine biosynthesis110
salvage pathways of pyrimidine ribonucleotides936
salvage pathways of pyrimidine deoxyribonucleotides432
pyrimidine ribonucleosides degradation II28
pyrimidine salvage pathway611
superpathway of ribose and deoxyribose phosphate degradation024
(deoxy)ribose phosphate degradation018
purine and pyrimidine metabolism032
uracil degradation II (reductive)310
salvage pathways of purine and pyrimidine nucleotides030
pyrimidine ribonucleosides degradation I07
AtMetExpress overview0109
Biochemical pathways: part I0466
Pyrimidine metabolism038
GABA metabolism (aka GHB)1128
Pyrimidine metabolism and related diseases1844
Beta-alanine biosynthesis III39
DNA replication and repair5315
DNA repair4610
Base Excision Repair, AP site formation by depyrimidination32

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.53080.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency6.13170.000714.592883.7951AID1259369
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.64890.000229.305416,493.5996AID1259244
gemininHomo sapiens (human)Potency3.16230.004611.374133.4983AID624297
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency54.64890.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency54.64890.001551.739315,848.9004AID1259244
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Uracil-DNA GlycosylaseThermus thermophilusKi0.08800.08800.08800.0880AID977610
Protein cereblonHomo sapiens (human)IC50 (µMol)415.00000.28601.70663.0000AID1685005
Protein cereblonHomo sapiens (human)Ki212.00001.49006.580010.0000AID1685005
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
protein ubiquitinationProtein cereblonHomo sapiens (human)
positive regulation of Wnt signaling pathwayProtein cereblonHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
positive regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
negative regulation of monoatomic ion transmembrane transportProtein cereblonHomo sapiens (human)
locomotory exploration behaviorProtein cereblonHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingProtein cereblonHomo sapiens (human)
transmembrane transporter bindingProtein cereblonHomo sapiens (human)
metal ion bindingProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleusProtein cereblonHomo sapiens (human)
cytoplasmProtein cereblonHomo sapiens (human)
cytosolProtein cereblonHomo sapiens (human)
membraneProtein cereblonHomo sapiens (human)
perinuclear region of cytoplasmProtein cereblonHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (66)

Assay IDTitleYearJournalArticle
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1530048Inhibition of Streptococcus pyogenes SrtA deltaN81 mutant expressed in Escherichia coli BL21(DE3) at 100 uM using Abz-LPETA-Dap(Dnp) as substrate preincubated for 10 mins followed by substrate addition measured every min for 2.5 hrs by fluorimetric assay 2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of potential antivirulence agents by substitution-oriented screening for inhibitors of Streptococcus pyogenes sortase A.
AID123974Hypnotic activity in ddN strain mice by the iv administration of 0.5 mmol/kg; No activity.1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant.
AID501987Antiviral activity against Influenza B virus Florida/4/2006 infected in MDCK cells2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Novel nucleosides as potent influenza viral inhibitors.
AID123964Hypnotic activity expressed as sleeping time was determined in ddN strain mice by the icv administration of 2.0 uMol/mouse of the compound; None indicates that the mouse could not fall into sleep1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant.
AID1685005Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence by MST based assay2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID1332258Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Biotransformation of isofraxetin-6-O-β-d-glucopyranoside by Angelica sinensis (Oliv.) Diels callus.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID1149715Antitumor activity against mouse B16 cells allografted in C57Bl/6 mouse at 25 mg/kg/day, ip administered for 2 weeks relative to control1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antitumor agents. 25. Synthesis and antitumor activity of uracil and thymine alpha-methylene-gamma-lactones and related derivatives.
AID453744Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation by continuous spectrophotometric assay in presence of 150 mM NH4Cl2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID501986Antiviral activity against Influenza A virus H5N1 Vietnam/1203/2004H infected in MDCK cells2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Novel nucleosides as potent influenza viral inhibitors.
AID1149714Antitumor activity against mouse P388 cells allografted in DBA/2 mouse at 25 mg/kg/day, ip administered for 2 weeks relative to control1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antitumor agents. 25. Synthesis and antitumor activity of uracil and thymine alpha-methylene-gamma-lactones and related derivatives.
AID453747Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation by continuous spectrophotometric assay in presence of 10 mM L-glutamine and 0.15 mM 2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID1082823Toxicity in Artemia salina (brine shrimp) at 28 degC after 48 hr2012Journal of agricultural and food chemistry, Apr-04, Volume: 60, Issue:13
Metabolites from Aspergillus fumigatus, an endophytic fungus associated with Melia azedarach, and their antifungal, antifeedant, and toxic activities.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID501988Cytotoxicity against MDCK cells2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Novel nucleosides as potent influenza viral inhibitors.
AID140060Tested for PB (pentobarbital)-induced sleep effect expressed as percent control of sleeping time at a dosage (icv) of 1.0 uM concentration1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1372697Inhibition of mushroom tyrosinase using tyrosine as substrate pretreated for 5 mins followed by substrate addition measured after 20 mins by ELISA2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
Characterization of tyrosinase inhibitory constituents from the aerial parts of Humulus japonicus using LC-MS/MS coupled online assay.
AID1149713Antitumor activity against rat Walker 256 cells allografted in Sprague-Dawley rat at 2.5 mg/kg/day, ip relative to control1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antitumor agents. 25. Synthesis and antitumor activity of uracil and thymine alpha-methylene-gamma-lactones and related derivatives.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2003Journal of molecular biology, Oct-24, Volume: 333, Issue:3
Crystal structure of a family 4 uracil-DNA glycosylase from Thermus thermophilus HB8.
AID1811Experimentally measured binding affinity data derived from PDB2003Journal of molecular biology, Oct-24, Volume: 333, Issue:3
Crystal structure of a family 4 uracil-DNA glycosylase from Thermus thermophilus HB8.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10,755)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904641 (43.15)18.7374
1990's1304 (12.12)18.2507
2000's2061 (19.16)29.6817
2010's2140 (19.90)24.3611
2020's609 (5.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.38 (24.57)
Research Supply Index9.39 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index135.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (73.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials715 (6.33%)5.53%
Reviews557 (4.93%)6.00%
Case Studies537 (4.75%)4.05%
Observational40 (0.35%)0.25%
Other9,451 (83.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]